----item----
version: 1
id: {DCBF2C1C-9BB2-4D72-8B7D-6337F5E2EB15}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/VC Funding 2013
parent: {D5B965D3-AC3D-4A7F-90E6-65193022C6B5}
name: VC Funding 2013
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: cefba3aa-437f-4980-9ff4-bfbf5e1a9687

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 969

<p>   <tbody> <tr> </tr> <tr> <td> <tbody> <tr> <td>Are you betting on medtech's hottest areas?<a></a><br> <em>By Tina Tan, Editor</em><br> Find out who's investing in what with Clinica's venture/growth financing table, updated regularly with the latest investment deals. </td> </tr> <tr> <td><b>VC Funding 2013</b></td> <td><a><b>VC Funding 2012</b></a></td> <td><b><a>VC Funding 2011</a></b></td> <td><b><a>FREE TRIAL</a></b></td> </tr> </tbody> </td> </tr> <tr> <td><a></a></td> <td><div><a></a></div></td> <td><a></a></td> <td><div><a></a></div></td> <td><a></a></td> <td><a></a></td> <td><a></a></td> <td><a></a></td> </tr> <tr> <td><div><a>Deals</a></div></td> <td><div><a>MandA </a></div></td> <td><div><a>Financials</a></div></td> <td><div><a>Funding </a></div></td> <td><div><a>Legal</a></div></td> <td><div><a>Start-ups and SMEs </a></div></td> <td><div><a>Market Monitor </a></div></td> <td><div><a>Google Map: MandA 2010 </a></div></td> </tr> </tbody>  </p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 15

VC Funding 2013
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 150787

<p>  <table> <tbody> <tr> </tr> <tr> <td colspan="8" scope="row" widtd="101"><table> <tbody> <tr> <td colspan="4" scope="row" widtd="101">Are you betting on medtech's hottest areas?<a name="top" id="top"></a><br> <em>By Tina Tan, Editor</em><br> Find out who's investing in what with Clinica's venture/growth financing table, updated regularly with the latest investment deals. </td> </tr> <tr> <td bgcolor="#cccccc" scope="row" widtd="101"><b>VC Funding 2013</b></td> <td bgcolor="#666666" scope="row" widtd="101"><a href="http://www.clinica.co.uk/VC-Funding/_2012/" class="optionsLink"><b>VC Funding 2012</b></a></td> <td bgcolor="#666666" scope="row" widtd="101"><b><a href="http://www.clinica.co.uk/VC-Funding/_2011/" class="optionsLink">VC Funding 2011</a></b></td> <td bgcolor="#666666" scope="row" widtd="101"><b><a href="http://www.clinica.co.uk/freetrial/" class="optionsLink">FREE TRIAL</a></b></td> </tr> </tbody> </table></td> </tr> <tr> <td><a href="http://www.clinica.co.uk/business/"><img src="-/media/A41DB0E6789340E3BBE2BB586EBE4293.ashx" alt="Deals" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td scope="row" widtd="101"><div><a href="http://www.clinica.co.uk/business/manda/"><img src="-/media/1594690D6C314ABFA668C2F281D90DEC.ashx" alt="MandA" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></div></td> <td><a href="http://www.clinica.co.uk/business/financials/"><img src="-/media/873669F6772642DC9C0C091A39B44486.ashx" alt="Financials" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td><div><a href="http://www.clinica.co.uk/business/funding/"><img src="-/media/B1AB1227A20C433897DB3C8B2F140E45.ashx" alt="Funding" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></div></td> <td><a href="http://www.clinica.co.uk/business/legal/"><img src="-/media/7D0516FC157A4E1F896F543962188904.ashx" alt="Legal" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td><a href="http://www.clinica.co.uk/business/start-upssmes/"><img src="-/media/66EE0878ED2E4CEC9D21449351C40077.ashx" alt="Start-ups and SMEs" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td><a href="http://www.clinica.co.uk/business/marketmonitor/"><img src="-/media/808B4B2204F542438455FA3DB83F4C28.ashx" alt="Market Monitor" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td><a href="http://www.clinica.co.uk/ma2/"><img src="-/media/7183F022AB364B8C8C43E7EC13518288.ashx" alt="Google Map" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> </tr> <tr> <td scope="row" widtd="101"><div><a href="http://www.clinica.co.uk/business/" class="optionsLink">Deals</a></div></td> <td scope="row" widtd="101"><div><a href="http://www.clinica.co.uk/business/manda/" class="optionsLink">MandA </a></div></td> <td><div><a href="http://www.clinica.co.uk/business/financials/" class="optionsLink">Financials</a></div></td> <td><div><a href="http://www.clinica.co.uk/business/funding/" class="optionsLink">Funding </a></div></td> <td><div><a href="http://www.clinica.co.uk/business/legal/" class="optionsLink">Legal</a></div></td> <td><div><a href="http://www.clinica.co.uk/business/start-upssmes/" class="optionsLink">Start-ups and SMEs </a></div></td> <td><div><a href="http://www.clinica.co.uk/business/marketmonitor/" class="optionsLink">Market Monitor </a></div></td> <td><div><a href="http://www.clinica.co.uk/ma2/" class="optionsLink">Google Map: MandA 2010 </a></div></td> </tr> </tbody> </table> </p> <p> &nbsp; </p> <table> <tr bgcolor="#C5E2E2"> <th scope="col"> <p> <b>Company</b> </p> </th> <th scope="col"> <p> <b>Sector</b> </p> </th> <th scope="col"> <p> <b>Technology</b> </p> </th> <th scope="col"> <p> <b>Investors to date</b> </p> </th> <th scope="col"> <p> <b>Amount raised</b> </p> </th> <th scope="col"> <p> <b>Financing round</b> </p> </th> <th scope="col"> <p> <b>Total raised by company</b> </p> </th> <th scope="col"> <p> <b>Month</b> </p> </th> </tr> <tr> <td> <p> <b>JANUARY</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> SPR Therapeutics (Cleveland, OH, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> SPR specialises in peripheral nerve stimulation to treat pain. It has developed the SmartPatch system that stimulates the peripheral nerves without being in direct contact with them. SPR also has the Micropulse fully implantable system, positioned as a second-line treatment, for longer term pain management. </p> </td> <td> <p> NDI Healthcare Fund, Public Square Partners, individual investors </p> </td> <td> <p> $5m </p> </td> <td> <p> Series A </p> </td> <td> <p> $10.7m ($5m equity, remainder from grants and loans) </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Great Basin Corporation (Salt Lake City, UT, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> GBC develops molecular diagnostic tests for rapid multi-pathogen diagnosis of infectious diseases. It has a FDA-cleared test to detect C difficile in suspected hospital-acquired infections, and developing products for fungal pathogens, nasal MRSA and for Staphylococcal infections.&nbsp; </p> </td> <td> <p> Private investors </p> </td> <td> <p> $9.5m </p> </td> <td> <p> Series B </p> </td> <td> <p> $20.25m (includes $3.9m bridge financing) </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> PolyPid (Petach Tikva, Israel) </p> </td> <td> <p> Drug delivery </p> </td> <td> <p> The PolyPid family of drug carriers is based on a fusion between polymers and lipid-based systems. The first product is BonyPid, a bone void filler that is nano-coated with a PolyPid biodegradable formulation. The coating gradually releases one or more selected antibiotics into its surroundings, to prevent infection and support bone recovery. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2.4m </p> </td> <td> <p> Series C </p> </td> <td> <p> $5.8m </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Halt Medical (Brentwood, CA, US) </p> </td> <td> <p> Women's health </p> </td> <td> <p> The Acessa system is FDA-cleared to treat uterine fibroids, It uses radiofrequency thermal energy to ablate the fibroids in a minimally invasive procedure, while sparing healthy tissue. </p> </td> <td> <p> American Capital </p> </td> <td> <p> $15m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Tryton Medical (Durham, NC, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Tryton's Side Branch Stent System is based on its Tri-zone technology for treating challenging bifurcated lesions. The stent is CE marked and not yet approved in the US. </p> </td> <td> <p> PTV Sciences, RiverVest Venture Partners, Spray Venture Partners, 3x5 Special Opportunity Fund </p> </td> <td> <p> $24m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Monteris Medical&nbsp; (Plymouth, MN, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> Monteris markets the NeuroBlate system, a neurosurgical ablation system for difficult-to-treat brain tumours. </p> </td> <td> <p> Business Development Bank of Canada, SWMF Life Science Fund and individual investors </p> </td> <td> <p> $7.8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Crescendo Bioscience (South San Francisco, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Crescendo's flagship molecular diagnostic product is Vectra DA, a multi-biomarker blood test to assess disease activity in rheumatoid arthritis. </p> </td> <td> <p> Skyline Ventures, Safeguard Scientifics, Mohr Davidow Ventures, Kleiner Perkins Caufield and Byers, aeris CAPITAL and others </p> </td> <td> <p> $28m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed&nbsp; </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> eZono (Jena,&nbsp; Germany ) </p> </td> <td> <p> Imaging </p> </td> <td> <p> The eZono 3000 is said to be the first tablet-style portable ultrasound system. The device is designed for emerging ultrasound applications such as regional anaesthesia, intensive care and emergency medicine. </p> </td> <td> <p> MVM Life Science Partners and others </p> </td> <td> <p> $10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Spinomix (Lausanne, Switzerland ) </p> </td> <td> <p> IVD </p> </td> <td> <p> Spinomix focuses on high-quality yet low-cost molecular diagnostic solutions, based on its MagPhase&nbsp; automated sample preparation platform and FibroTap fibrinogen-based technology to separate targeted cells and molecules within routine sample collection tubes. </p> </td> <td> <p> Debiopharm Group </p> </td> <td> <p> $3m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> ArthroCAD (Ayer, MA, US) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> ArthroCAD is developing a product for total hip arthroplasty. </p> </td> <td> <p> Private investors </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> AxioMed (Garfield Heights, OH, US) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> AxioMed specialises in spinal orthopaedics; its products are designed to restore spinal function. </p> </td> <td> <p> CID Equity Partners, Early Stage Partners, Investor Growth Capital, MB Venture Partners, Primus Capital Funds, Reservoir Venture Partners, Thomas McNerney and Partners, Charter Oak Equity, Blue Chip </p> </td> <td> <p> $3.6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Angioslide (Natanya, Israel) </p> </td> <td> <p> Peripheral vascular </p> </td> <td> <p> The PROTEUS device by Angioslide, used to treat peripheral artery disease, combines balloon angioplasty with debris capture and removal. The device is FDA-cleared and CE marked for use in lower limbs. </p> </td> <td> <p> TriVentures, Biostar, Viola Partners, Agate, XT Investments </p> </td> <td> <p> $6.3m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Ovuline (Boston, MA, US) </p> </td> <td> <p> Women's health </p> </td> <td> <p> &nbsp;Smart Fertility is a mobile and web-based technology that helps to track a woman's fertility and increase her chances of pregnancy. </p> </td> <td> <p> Lightbank, Launch Capital, LionBird, Techstars </p> </td> <td> <p> $1.4m </p> </td> <td> <p> Seed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Lamellar Biomedical (Edinburgh, Scotland, UK) </p> </td> <td> <p> Biologics </p> </td> <td> <p> Lamellar Biomedical is developing medicines and medical devices based on its Lamellasomes technology platform, synthetic mimetics of naturally-occuring vesicles called lamellar bodies. Its lead product, LMS-611 will be regulated as a Class Iib device fore treating dry eye disease and radiotherapy-induced xerostomia, commonly known as dry mouth.&nbsp; </p> </td> <td> <p> Barwell, Scottish Enterprise, TRI Capital, Invesco Perpertual </p> </td> <td> <p> &pound;3.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> EndoChoice (Alpharetta, GA, US and Caesarea, Israel) </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> EndoChoice, through its acquisition of Israeli company Peer Medical, offers proprietary endoscopy devices for gastrointestinal applications.&nbsp; </p> </td> <td> <p> Sequoia Capital and other investors </p> </td> <td> <p> $43m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> PatientSafe Solutions (San Diego, CA, US) </p> </td> <td> <p> Healthcare IT </p> </td> <td> <p> PatientSafe specialises in &quot;smart&quot; point-of-care mobile technologies to improve and streamline workflow and communications among healthcare workers. Its first product is the PatientTouch system. </p> </td> <td> <p> Merck Global Health Innovation, Camden Partners, TPG Capital, Psilos Group </p> </td> <td> <p> $20m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Micro Interventional Devices (Bethlehem, PA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> MID's products incorporate its proprietary rapid deployment anchoring technology. Permaseal is designed to facilitate sutureless transmycardial access and spontaneous closure during structural heart repair procedures. The Endovalve is a percutaneous mitral valve replacement system. </p> </td> <td> <p> Originate Ventures, Battelle Ventures </p> </td> <td> <p> $3.5m </p> </td> <td> <p> Series B-1 </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Ceterix Orthopaedics (Menlo Park, CA, US) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> Ceterix's surgical technology for hip, knee and shoulder arthroscopic procedures enable surgeons to place stitches in very tight joint compartments, while protecting surrounding structures such as nerves, arteries and cartilage. </p> </td> <td> <p> Novo Ventures, Versant Ventures, 5AM Ventures </p> </td> <td> <p> $19.5m </p> </td> <td> <p> Series B </p> </td> <td> <p> $27.6m </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Lophius Biosciences (Regensburg, Germany) </p> </td> <td> <p> IVD </p> </td> <td> <p> Lophius specialises in T-cell-based diagnostics. Its CE-marked products include the T-Track CMV and EBV tests, and the T-Track TB test. </p> </td> <td> <p> VRD, WIC, S-Refit, HighTech Grunderfonds, Bayern Kapital and business angels </p> </td> <td> <p> &euro;4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Medisse (Ede, The Netherlands) </p> </td> <td> <p> Biomaterials </p> </td> <td> <p> Medisse has developed the resorbable FlexiSurge Adhesion Barrier, used in surgery as a physical barrier to prevent fibrous tissue from growing across to other organs. </p> </td> <td> <p> IIG, BioGeneration Ventures, Omnes Capital, Credit Agricole Private Equity </p> </td> <td> <p> &euro;2.6m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Ocular Therapeutix (Bedford, MA, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Ocular Therapeutix is developing a range of ophthalmic products, including drug-eluting punctum plugs for glaucoma, intravitreal injections and sealants, all using its proprietary hydrogel technology. </p> </td> <td> <p> Polaris Ventures, SV Life Sciences, Sparta, Ascension Health Ventures </p> </td> <td> <p> $23.8m </p> </td> <td> <p> Series D extension </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> TruTouch Technologies (Framingham, MA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> TruTouch specialises in noninvasive biometric alcohol detection systems that dose not require any samples, any disposables nor any training to operate. Its platform technology can be applied to other medical diagnostic systems, among other things. </p> </td> <td> <p> Launchpad Venture Group, iTulip </p> </td> <td> <p> $4.3m </p> </td> <td> <p> Series B-1 </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Ivantis (Irvine, CA, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Ivantis is conducting clinical trials of its Hydrus Microstent used to manage glaucoma. the device is roughly the size of an eyelash and is implanted in the eye to reestablish the patient's natural outflow of aqueous humour and reducing eye pressure. </p> </td> <td> <p> Ascension Health Ventures, New Enterprise Associates, Delphi Ventures, MemorialCare Innovation Fund </p> </td> <td> <p> $27m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Osseon Therapeutics (Santa Rosa, CA, US) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> Osseon has developed a range of products for treating veterbral compression fractures. </p> </td> <td> <p> Private investor </p> </td> <td> <p> $14m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> Syapse (Palo Alto, CA, US) </p> </td> <td> <p> Healthcare IT/IVD </p> </td> <td> <p> Syapse is developing software for omics-based diagnostics. Its first product, Syapse Discovery is designed for companies and lbas deploying next-generation sequencing-based diagnostics. </p> </td> <td> <p> The Social+Capital Partnership </p> </td> <td> <p> $3m </p> </td> <td> <p> Series A </p> </td> <td> <p> n/a </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> eHealth Technologies (New York, NY, US) </p> </td> <td> <p> Healthcare IT </p> </td> <td> <p> eHealth provides IT solutions to streamline workflow and the flow of data in hospitals. </p> </td> <td> <p> Merck Global Health Innovation Fund </p> </td> <td> <p> $6m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Jan </p> </td> </tr> <tr> <td> <p> <b>FEBRUARY</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Novian Health (Chicago, IL, US and Evry, France) </p> </td> <td> <p> Cancer therapy </p> </td> <td> <p> Novian's Novilase Interstitial Laser Therapy, positioned as an alternative to lumpectomy, is designed to ablate tumours in early-stage breast cancer patients. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $11m </p> </td> <td> <p> Series A-1 </p> </td> <td> <p> n/a </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Exosome Diagnostics (NEw York, NY, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Exosome is developing biofluid-based molecular diagnostic tests for personalised medicine </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> CyVek (Wallingford, CT, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> CyVek's CyPlex is an integrated test system that includes a microfluidic cartridge that allows multi-biomarker analysis from very small amounts of biological samples. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5.5m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Sotera Wireless (San Diego, CA, US) </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> Sotera has developed the ViSi Mobile platform that continuously monitors a patients' vital signs in and out of bed, as well as when in motion. </p> </td> <td> <p> Safeguard Scientifics, Delphi Ventures, Sanderling Ventures, Qualcomm Ventures, EDBI, Intel Capital, Cerner Capital, West Health Investment Fund </p> </td> <td> <p> $14.8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> GluMetrics (Irvine, CA, US) </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> The GluCath intravascular continuous blood glucose monitor is designed for use on critically ill patients in the ICU. </p> </td> <td> <p> New Leaf Ventures, Kaiser Permanente Ventures, Advanced Technology Ventures, Versant Ventures, among others </p> </td> <td> <p> $3m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Glaukos (Laguna Hills, CA, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Glaukos has developed the iStent range of eye implants for managing glaucoma. The iStent trabecular micro-bypass device is the most advanced product; it is FDA-approved and ready for US commercial launch. </p> </td> <td> <p> Meritech Capital Partners,Versant Ventures, Domain Associates, Montreux Equity Partners, InterWest Partners, Frazier Healthcare, OrbiMed Advisors, Gund Investment </p> </td> <td> <p> $30m </p> </td> <td> <p> Series F </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Qvanteq (Zurich, Switzerland) </p> </td> <td> <p> Cardiovascular </p> </td> <td> <p> Qvanteq is developing a bioactive, coating-free coronary stent. The device has shown, in preclinical studies, to be comparable to bare metal stents and comparable, or even better, than drug-eluting stents. </p> </td> <td> <p> Private investors </p> </td> <td> <p> CHF4m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Aviir (Irvine, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Aviir's MIRISK VP technology consists of a simple blood test that assesses the patient's risk of a heart attack within the next five years. </p> </td> <td> <p> Merck Global Health Innovation Fund, Partners &amp; Partners, Bay City Capital, Aberdare Ventures, New Leaf Venture Partners </p> </td> <td> <p> $10m </p> </td> <td> <p> Second tranche of undisclosed equity round </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Entourage Medical Technologies (Menlo Park, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Entourage is developing left ventricular access and closure devices for structural heart disease </p></td> <td> <p> Undisclosed </p> </td> <td> <p> $3.25m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> AFcell Medical (Parsippany, NJ, US) </p> </td> <td> <p> Biomaterials </p> </td> <td> <p> AFcell's AmnioClear tissue graft is made from human amniotic membrane. The grafts are used to recover internal structures such as tendon or spine to protect them during the healing process. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $1.2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Holaira (Plymouth, MN, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> Holaira is developing a catheter-based system for conducting targeted lung denervation to treat chronic obstructive pulmonary disease. </p> </td> <td> <p> Advanced Technology Ventures, Morganthaler Ventures, Split Rock Partners, Versant Ventures </p> </td> <td> <p> $10m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> BAROnova (Goleta, CA, US) </p> </td> <td> <p> Obesity </p> </td> <td> <p> The TransPyloric Shuttle device is inserted into the stomach through the mouth via an endoscopic procedure. The device causes the patient's stomach to fill up faster and potentially delay gastric emptying, helping weight loss. </p> </td> <td> <p> Arboretum, Boston Scientific, Highland Capital Partners, Lumira Capital, Onset Ventures, Sante Ventures </p> </td> <td> <p> $27.3m </p> </td> <td> <p> Series C </p> </td> <td> <p> $41.3m </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Cohera Medical (Pittsburgh, PA, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> Cohera is commercialising in Europe its TissuGlu internal surgical adhesive for large flap surgeries. </p> </td> <td> <p> Private investors </p> </td> <td> <p> $7.3m </p> </td> <td> <p> Part of a $17m Series D </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Multiplicom (Niel, Belgium) </p> </td> <td> <p> IVD </p> </td> <td> <p> Multiplicom specialises in molecular diagnostic tests used in personalised medicine. Its tests are used in cancer genetics, diagnosing genetic, neurological and kidney disorders, among other things. </p> </td> <td> <p> PMV, RMM (Rudi Marien), Qbic ARKIV Fund, Gimv, VIB </p> </td> <td> <p> &euro;5.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> PolyActiva (Melbourne, Australia) </p> </td> <td> <p> Drug delivery </p> </td> <td> <p> PolyActiva has developed a drug-polymer conjugate technology that allows sustained-release, site-specific drug delivery from devices and other products. </p> </td> <td> <p> Medical Research Commercialisation Fund, Brandon Biosciences Fund, Yuuwa Capital and angel investors </p> </td> <td> <p> Aus$9.2m </p> </td> <td> <p> Series B </p> </td> <td> <p> Aus$10.8m </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Gynesonics (Redwood City, CA, US) </p> </td> <td> <p> Women's health </p> </td> <td> <p> Gynesonics' VizAblate is a CE-marked transcervical, ultrasound-guideded system for treating uterine fibroids. </p> </td> <td> <p> HBM Partners, Correlation Ventures, Abingworth, Advanced Technology Ventures, InterWest Partners </p> </td> <td> <p> $21m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> SynapDx (Lexington, MA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> SynapDx is developing a blood-based test for autism spectrum disorder. </p> </td> <td> <p> LabCorp, North Bridge Venture Partners, General Catalyst Partners </p> </td> <td> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Nuclea Biotech (Pittsfield, MA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Nuclea develops diagnostic tests for colon, breast, lung and prostate cancer, and also biomarker and drug discovery divisions </p> <p></td> <td> <p> Undisclosed </p> </td> <td> <p> $1m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Over $20m </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Sapiens Steering Brain Stimulation (Eindhoven, the Netherlands and Munich, Germany) </p> </td> <td> <p> Neurology </p> </td> <td> <p> Sapiens is developing a deep brain stimulation system for treating Parkinson's disease </p> </td> <td> <p> INKEF Capital, Wellington Partners, Edmond de Rothschild Investment Partners, Life Sciences Partners, The Wellcome Trust </p> </td> <td> <p> &euro;7.5m </p> </td> <td> <p> Series A-2 </p> </td> <td> <p> &euro;24m </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Glide Pharma (Oxford, UK) </p> </td> <td> <p> Drug delivery </p> </td> <td> <p> Glide specialises in needle-free administration of solid dose formulations, using its Glide SDI solid dose injector system </p> </td> <td> <p> Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners, Hygea VCT </p> </td> <td> <p> &pound;14.0m ($21.4m) </p> </td> <td> <p> Series E </p> </td> <td> <p> &pound;24.9m </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Blaze Bioscience (Seattle, WA, US) </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> Blaze's Tumor Paint technology provides real-time high-resolution visualisation of solid tumours by binding to and illuminating cancer cells to help surgical removal. </p> </td> <td> <p> Private investors </p> </td> <td> <p> $8.5m </p> </td> <td> <p> Series A </p> </td> <td> <p> $9.8m </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Intersect ENT (Menlo Park, CA, US) </p> </td> <td> <p> ENT </p> </td> <td> <p> Intersect has developed Propel, a steroid-releasing implants for patients with chronic sinusitis </p> </td> <td> <p> Norwest Venture Partners, Kleiner Perkins Caufield &amp; Byers, US Venture Partners, PTV Sciences, Medtronic </p> </td> <td> <p> $30m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Cipher Surgical (Coventry, UK) </p> </td> <td> <p> Surgery </p> </td> <td> <p> Cipher is looking to CE mark its OpClear device for maintaining a clean, clear distal window of the laparscope during surgery. </p> </td> <td> <p> Envestors </p> </td> <td> <p> &pound;1.2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Quotient Biodiagnostics (Edinburgh, Scotland and Newtown, PA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Quotient specialises in blood transfusion diagnostics. It is developing its next-gen automated platform. </p> </td> <td> <p> Galen Partners, Paul Cowan (Quotient CEO and founder) </p> </td> <td> <p> $5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $19.2m (over last 18 months) </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> CardioKinetix (Menlo Park, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> CardioKinetix's Parachute device, currently in US pivotal trials, targets the segment of heart failure patients who have an enlarged left ventricle caused by a heart attack. </p> </td> <td> <p> Panorama Capital, US Venture PArtners, JPMorgan Partners, New LEaf Venture Partners, SV Life Sciences, H&amp;Q Healthcare Inestors, H&amp;Q Life Sciences Investors </p> </td> <td> <p> $23m </p> </td> <td> <p> Series E-2 </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> Enopace Biomedical (Israel) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Enopace is developing an endovascular microstimulator that increases cardiac efficiency by reducing left ventricular workload in heart failure patients </p> </td> <td> <p> Sorin, Rainbow Medical </p> </td> <td> <p> $5m (from Sorin alone. Includes milestones and buyout option) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $13m (from Sorin alone) </p> </td> <td> <p> Feb </p> </td> </tr> <tr> <td> <p> <b>MARCH</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Swallow Solutions (Madison, WI, US) </p> </td> <td> <p> ENT </p> </td> <td> <p> Swallow Solutions is focused on products to help patients with dysphagia, the reduced ability to swallow. </p> </td> <td> <p> Venture Management, NEW Capital Fund, Wisconsin Investment Partners and individual investors </p> </td> <td> <p> $1m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> Diagnostic Healthcare (Altrincham, UK) </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> Diagnostic Healthcare offers a range diagnostic imaging services for the UK NHS </p> </td> <td> <p> The North West Fund for Biomedical </p> </td> <td> <p> &pound;1m ($1.5m) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> Endosense (Geneva, Switzerland) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Endosense is expanding EU commercialisation of its TactiCath contact force-sensing ablation catheter, for treating cardiac arrhythmias. THe device is undergoing trials for US approval </p> </td> <td> <p> Unnamed strategic industry partner, Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners, Initiative Capital Romandie, NGN Capital </p> </td> <td> <p> CHF4m ($4.3m) </p> </td> <td> <p> Series C-2 </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> Avedro (Waltham, MA, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Avedro has developed systems for perfoming corneal crosslinking, which has applications in cataract and refractive surgery </p> </td> <td> <p> Abingworth, Third Point, Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Partners, BOrealis Ventures, Echelon Ventures </p> </td> <td> <p> $43m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> Saladax Biomedical (Bethlehem, PA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Saladax commercialises the MyCare platform of companion diagnostics for new and existing therapeutics </p> </td> <td> <p> Shanghai Fosun Pharmaceutical; Excel Venture Management Partners, the Life Sciences Greenhouse of Central Pennsylvania and other angel investors </p> </td> <td> <p> $22.4m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> Nevro (Menlo Park, CA, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> Nevro's Senza high-frequency spinal cord stimulation is CE marked for treating chronic pain. The device is being trialled in the US. </p> </td> <td> <p> Novo Vnetures, New Enterprise Associates, Covidien Ventures, Accuitive Medical Ventures, Bay City Capital, Johnson &amp; Johnson Development Corporation, Mayo Clinica, MPM Capital, Three Arch Partners </p> </td> <td> <p> $48m </p> </td> <td> <p> Series C </p> </td> <td> <p> Approx $100m </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> NextGxDx (Nashville, TN, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> NextGxDx offers an online marketplace for healthcare professionals and hospitals where they can order genetic tests </p> </td> <td> <p> Angel investors </p> </td> <td> <p> $1m </p> </td> <td> <p> Series A-2 </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> MacuLogix (Hummelstown, PA, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> MacuLogix is developing the AdaptDx system to be a diagnostic tool for early detection and tracking of age-related macular degeneration. </p> </td> <td> <p> Berwind Private Equity, Roche Venture Fund, Life Sciences Greenhouse, Ben Franklin Technology Partners </p> </td> <td> <p> $3.6m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> EyeTechCare (Rillieux-la-Pape, France) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> EyeTechCare's CE-marked EyeOP1 is an ultrasound-based system for the noninvasive treatment of glaucoma, </p> </td> <td> <p> Private investor, Omnes Capital (Credit Agricole Private Equity), SHAM, CEA Investissement </p> </td> <td> <p> &euro;10m ($13m) </p> </td> <td> <p> Series C </p> </td> <td> <p> &euro;18.7m </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> Clearbridge BioMedics (Singapore) </p> </td> <td> <p> IVD </p> </td> <td> <p> Clearbridge's specialises in cancer diagnostic tests based on circulating tumour cells (CTCs). It has the ClearCell system which incorporate the CTChip, a proprietary microfluidic biochip that detects and isolates CTCs from blood. </p> </td> <td> <p> Vertex Venture, SPRING Seeds Capital, Clearbridge BSA, BioVeda, private investors </p> </td> <td> <p> S$9m ($7.2m) </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> Spiral Genetics(Seattle, WA, US) </p> </td> <td> <p> Bioinformatics </p> </td> <td> <p> Spiral Genetics offers DNA sequencing analysis services with a faster turnaround time. </p> </td> <td> <p> Draper Fisher Jurvetson </p> </td> <td> <p> $3m </p> </td> <td> <p> Series A </p> </td> <td> <p> $3.7m </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> DC Devices (Tewksbury, MA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> DC Devices is developing a transcatheter device, the IASD (InterAtrial Shunt Device), for diastolic heart failure (DHF). The system is desigend to relieve increased left atrial pressure, the main cause of DHF. </p> </td> <td> <p> Lumira Catpial, Third Rock Ventures, General Catalyst </p> </td> <td> <p> $9m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> Topera Medical (San Diego, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Topera's FDA 510(k)-cleared RhythmView 3D mapping system is used for more targeted heart ablation to treat arrhythmia. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $25m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> Lumora (Cambridge, UK) </p> </td> <td> <p> IVD </p> </td> <td> <p> Lumora is commercialising its molecular diagnostic technology, the BART (bioluminescent assay in real time) system. </p> </td> <td> <p> Tate &amp; Lyle Ventures, Catapult Ventures Managers and Cambridge University </p> </td> <td> <p> &pound;700,000 ($1m) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> SynCardia Systems (Tucson, AZ, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> SynCardia is developing the next-generation of its Total Artificial Heart device, used as a bridge to transplant for patients suffering from end-stage heart failure </p> </td> <td> <p> Athyrium Opportunities Fund and others </p> </td> <td> <p> $19m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> nContact (Morrisville, NC, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> nContact has developed two epicardial ablation devices, the Numeris and EPi-Sense Coagulation System with VisiTrax, for treating atrial fibrillation. </p> </td> <td> <p> Harbert Venture Partners, ZMV Associates and others </p> </td> <td> <p> $6.7m </p> </td> <td> <p> First tranche of series E </p> </td> <td> <p> Around $49m </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> OriGene Technologies (Rockville, MD, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> OriGene has developed an array of ultra-specific monoclonal antibodies called UltraMAD which are used in research and diagnostic products. </p> </td> <td> <p> Qiming Venture Partners, Kleiner Perkins Caufiled Byers China, IDG-Accel </p> </td> <td> <p> $21.3m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> CryoTherapeutics (Cologne, Germany) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> CryoTherapeutics is developing a catheter-based cryotherapy system for treating unstable atherosclerotic plaques. </p> </td> <td> <p> Peppermint VenturePartners, NRW.BANL, High-Tech Gr√ºnderfonds, Getz Brothers, private investors </p> </td> <td> <p> &euro;3m ($3.9m) </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> Minimally Invasive Devices (Columbus, OH, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> MID is expanding commercialisation iof its FDA-approved FloShield laparascopic vision system, designed to stop the optics of the laparascope being obscured during surgery. </p> </td> <td> <p> Canaan Partners, Charter Life Science </p> </td> <td> <p> $9m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> EndoStim (St Louis, MI, US and The Hague, The Netherlands) </p> </td> <td> <p> Gastroenterology </p> </td> <td> <p> EndoStim has developed a pacemaker-like device that delivers electrostimulation to treat gastroesophageal reflux disorder. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $11m </p> </td> <td> <p> Part of a planned $17m round </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> Asuragen (Austin, TX, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Asuragen develops and commercialises miRNA-based theapeutic and diagnostic products </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $7.5m </p> </td> <td> <p> Part of a planned $15m round </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> GenapSys (Redwood City, CA, US) </p> </td> <td> <p> Genomics </p> </td> <td> <p> Stanford University spin-off GenapSys claims its gene sequencing technology can sequence the entire human genome in less than a day and for $30. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $8.5m </p> </td> <td> <p> Part of a planned $13.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> Bina Technologies (Redwood City, CA, US) </p> </td> <td> <p> Genomics </p> </td> <td> <p> Bina specialises in genetic data analysis. </p> </td> <td> <p> Sierra Ventures and others </p> </td> <td> <p> $6.25m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> T2 Biosystems (Lexington, MA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> T2 develops molecular diagnostic tests for infectious diesases, including Candid fungal infections and sepsis. </p> </td> <td> <p> Goldman Sachs, Flagship Ventures, Polaris Partners, Aisling Capital, Flybridge Capital Partners, Physic Ventures, Arcus Ventures, Partners Healthcare, Camros Capital, WS Investments </p> </td> <td> <p> $40m </p> </td> <td> <p> Series E </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> SynapDx (Lexington, MA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> SynapDx is developing a blood- based test for early detection fo Autism Spectrum Disorders. </p> </td> <td> <p> The Kraft Group, LabCorp, North Bridge Venture Partners, General Catalyst Partners </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> Vapotherm (Stevensville, MD, US) </p> </td> <td> <p> Respiratory disorders </p> </td> <td> <p> Vapotherm's FDA 510(k)-cleared Precision Flow Heliox system helps improve breathing in patients with respiratory difficulties such as asthma, croup and chronic obstructuve pulmonary disease. </p> </td> <td> <p> GE Asset Management, Cross Creek Capital, Integral Capital Partners, QuestMark Partners, Kaiser Permanente Ventures </p> </td> <td> <p> $26.4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> OrthoData (Louisville, KY, US) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> OrthoData is developing an implantable sensor that attaches to a rod in a pedical screw system used spinal fusion surgery; the sensor monitors the load on the rod to indicate how new bone is growing. </p> </td> <td> <p> JumpStart, Akron BioInvestments Funds, Queen City Angels, Kentucky Seed Capital Fund, Kentucky Science &amp; Technology Corporation, Commonwealth Seed Capital Fund, private investors </p> </td> <td> <p> $1.1m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Mar </p> </td> </tr> <tr> <td> <p> <b>APRIL</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Asthmapolis (Madison, WI, US) </p> </td> <td> <p> Respiratory disease </p> </td> <td> <p> Asthmapolis has an FDA-cleared sensor and mobile app system to improve management of asthma patients. The sensor attaches to the existing inhaler and keeps track of frequency of medication use. The smartphone app analyses this data and provides personalised feedback to the patient. </p> </td> <td> <p> The Social+Capital Partnership, California HealthCare Foundation and other investors </p> </td> <td> <p> $5m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> i-Optics (The Hague, The Netherlands) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> i-Optics specialises in eye diagnostics. Its products are the EasyScan retinal imaging camera and Cassini corneal topography. </p> </td> <td> <p> HBM Partners, NIBC Co-Investments Holding, Aescap Venture, De Hoge Dennen family fund and other investors </p> </td> <td> <p> &euro;11.8m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Renovis Surgical Technologies (Redlands, CA, US) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> Renovis develops and sells devices used in hip, knee, spine and trauma surgery. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $3.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Adagio Medical (Laguna Hills, CA, US) </p> </td> <td> <p> Cardiovascular </p> </td> <td> <p> Adagio is currently in stealth mode. It is focused on deveoping technologies for treating cardiovascular disease </p> </td> <td> <p> Fjord Ventures </p> </td> <td> <p> $2.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Curetis (Holzgerlingen, Germany) </p> </td> <td> <p> IVD </p> </td> <td> <p> The CE-marked Unyvero system is designed for fast multiplex DNA analysis. It is able to analyse a broad panel of bacteria and antibiotic resistances from a single sample in one run. Curetis's first CE-marked test is the P50, which focuses on pneumonia testing. It is also developing a test for implant and tissue infections. </p> </td> <td> <p> HBM Partners, aeris Capital, LSP Life Sciences Partners, Forbion Capital, BioMedInvest, Roche Venture Fund, CD Venture, KfW </p> </td> <td> <p> &euro;12.5m </p> </td> <td> <p> Series B </p> </td> <td> <p> &euro;49.1m </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Cervel Neurotech (Foster City, CA, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> Cervel is focused on transcranial magnetic stimulation for treating depression, pain and other conditions. </p> </td> <td> <p> DE Shaw Ventures, Aberdare Ventures and other investors </p> </td> <td> <p> $14.1m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Kaleidoscope Medical (Paradise Valley, AZ, US) </p> </td> <td> <p> Cardiovascular </p> </td> <td> <p> Kaleidoscope has developed a inferior vena caval filter for catching embolisms that can cause stroke. The filter can remain permanently in the patient, be removed after a certain time, or be reconfigured in the vessel to restore normal blood flow. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> EndoEvolution (North Chelmsford, MA, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> EndoEvolution is initiating commercialisation of its Endo360&ordm; range of minimally invasive automated suturing devices. </p> </td> <td> <p> Spring Bay Companies </p> </td> <td> <p> $5m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> ElectroCore (Morris Plains, NJ, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> ElectroCore's gammaCore device provides noninvasive vagus nerve stimulation to treat migraine, cluster headache and medication-overuse headache. It is approved for sale in EU and other countries outside the US. </p> </td> <td> <p> Merck, Easton Capital, Core Ventures and other investors </p> </td> <td> <p> $40m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Novaliq (Heidelberg, Germany) </p> </td> <td> <p> Drug delivery </p> </td> <td> <p> Novaliq specialises in topical formulations of poorly soluble drugs. </p> </td> <td> <p> Dievini Hopp </p> </td> <td> <p> &euro;13.9m ($18.1m) </p> </td> <td> <p> Series E </p> </td> <td> <p> &euro;27.1m ($35.2m) </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> DySIS Medical (Edinburgh, UK) </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> The DySIS colposcope is designed to improve the accuracy of detecting early stages of cervical cancer. </p> </td> <td> <p> Lundbeckfond Ventures, Albion Ventures, NBGI Ventures, Scottish Investment Bank </p> </td> <td> <p> &pound;7.4m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Altura Medical (Menlo Park, CA, US) </p> </td> <td> <p> Cardiovascular </p> </td> <td> <p> The Altura Endograft is designed to treat abdominal aortic aneurysm. </p> </td> <td> <p> SV Life Sciences, New Leaf Venture Partners, Advanced Technology Ventures and other investors </p> </td> <td> <p> $6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Biodesix (Boulder, CO, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Biodesix is focused on developing molecular diagnostic tests for personalised medicine. Its first product, VeriStrat, is a multivariate serum protein test to help doctors guide drug therapy for advanced non small cell lung cancer patients. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $8.8m </p> </td> <td> <p> Series D extension </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> ZetrOZ (Rochy Hill, CN, US) </p> </td> <td> <p> Therapeutic ultrasound </p> </td> <td> <p> ZetroOZ has developed a low-cost portable/wearable ultrasound system for treating musculoskeletal pain. </p> </td> <td> <p> Connecticut Innovations, Standard Oil Ventures, other individual investors </p> </td> <td> <p> $2.6m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> SuperSonic Imagine (Paris, France) </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> The Aixplorer ultrasound imaging system incorporates ShearWave Elastography technology for detecting tissue stiffness in a quantifiable and reproducible way and also Ultrafast Doppler for improved imaging quality. Aixplorer has been used for diagnosing various diseases including breast and prostate cancers, and chronic liver disease, among others. </p> </td> <td> <p> French Investment Fund, Alto Invest, Kuwait Life Sciences Company, Edmond de Rothschild Investment Partners, Auriga Partners, Omnes Capital (formerly Cr√©dit Agricole Private Equity), CDC Entreprises, NBGI Ventures, Wellington Partners, iXO Private Equity, and M√©rieux D√©veloppement </p> </td> <td> <p> &euro;28m ($36m) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Watermark Medical (Boca Raton, FL, US) </p> </td> <td> <p> Sleep disorders </p> </td> <td> <p> Watermark's ARES is a system for at-home sleep testing, to diagnosis patient's risk of sleep apnoea. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $32.2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Cheetah Medical (Tel-Aviv, Israel and Vancouver, WA, US) </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> Cheetah's CE-marked and US FDA-cleared NICOM is a noninvasive cardiac output and haemodynamic monitoring system, used on critically ill patients. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $14.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> to-BBB (Leiden, the Netherlands) </p> </td> <td> <p> Drug delivery </p> </td> <td> <p> to-BBB offers therapies for brain diseases by combining its proprietary G-Technology platform with existing drugs. Its lead product, 2B3-101 is being clinically trialled to assess its performance in patients with brain metastases of breast cancer and glioma, of small cell lung cancer and of melanoma. </p> </td> <td> <p> Aescap Venture, Antea Participaties, Jonghoud International, Industrial Bank of Taiwan Management Corporation. </p> </td> <td> <p> &euro;2.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> RainDance Technologies (Lexington, MA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> RainDance manufactures genetic research tools used for the early detection and monitoring of cancer and inherited diseases. </p> </td> <td> <p> Myriad Genetics, Mohr Davidow Ventures, Quaker BioVentures, Alloy Ventures, Acadia Woods Partners and Sectoral Asset Management. </p> </td> <td> <p> $20m </p> </td> <td> <p> Series E </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Topera (San Diego, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Topera's RhythmView workstation and FIRMap diagnostic catheter is a 3D heart mapping and targeting system to identify the sources that sustain complex cardiac arrhythmia such as atrial fibrillation. The system is poised for launch in the EU and US in 2013. </p> </td> <td> <p> New Enterprise Associates, unnamed strategy industry partner and other investors. </p> </td> <td> <p> $25m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> BioDirection (Tucson, AZ, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> BioDirection has developed a point-of-care blood test for mild traumatic brain injury, also referred to as concussion. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2.2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> iRyhthm Technologies (San Francisco, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> iRhythm's Zio Patch is FDA-cleared to be worn by the patient for 14 days of continuous cardiac monitoring. </p> </td> <td> <p> Norwest Venture Partners, New Leaf Ventures, Synergy Life Science Partners and Kaiser Permanente </p> </td> <td> <p> $16m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> dbMEDx (Denver, CO and Seattle, WA, US) </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> dbMEDx specialises automated, noninvasive scanning devices for a range of medical applications. Its Benchmark Bladder System is used for bladder volume measurement device and StatCVO is designed fo assessing central venous pressure and total blood volume. used in the diagnosis and treatment of medical conditions such as urinary tract infections. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $1.1m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Bioceptive (New Orleans, LA, US) </p> </td> <td> <p> Women's health </p> </td> <td> <p> Bioceptive is developing a product that simplifies the insertion of intrauterine devices, helping to reduce the number of adverse events during the procedure. </p> </td> <td> <p> New World Angels, First Light Ventures, Calvert Equity Portfolio </p> </td> <td> <p> $1.1m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> MC10 (Cambridge, MA, US) </p> </td> <td> <p> Stretchable electronics </p> </td> <td> <p> MC10 specialises in electronics that stretch and bend with the body's movements. Medtech applications of this technology include embedded sensors for monitoring critical physiological parameters. </p> </td> <td> <p> Medtronic, Braemar Energy Ventures and North Bridge Venture Partners among others </p> </td> <td> <p> $8m </p> </td> <td> <p> Part of Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Provista Diagnostics (Phoenix, AZ, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Provista's dtectDx molecular diagnostic platform is designed for detection and prognossis of cancers affecting women. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $6m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> Nasoform (Menlo Park, CA, US) </p> </td> <td> <p> ENT </p> </td> <td> <p> Nasoform is developing a minimally invasive device for treating collapsed nasal valves. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> AtheroMed (Menlo Park, CA, US) </p> </td> <td> <p> Cardiovascular </p> </td> <td> <p> The Phoenix atherectomy system is designed as a safe, easy-to-use front-line therapy for treating peripheral artery disease in the legs. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $6m </p> </td> <td> <p> Undiclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> April </p> </td> </tr> <tr> <td> <p> <b>MAY</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Natera (San Carlos, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Panorama is a noninvasive prenatal test. It uses maternal blood sample to detect common chromosomal abnormalities in the foetus, such as trisomy 21, trisomy 18 and trisomy 13, as well as monosomy X. </p> </td> <td> <p> OrbiMed Advisors, Harmony Partners, Claremont Creek Ventures, Lightspeed Venture Partners, Founders Fund, Sequoia Capital and other undisclosed investors </p></td> <td> <p> $54.6m </p> </td> <td> <p> Series E </p> </td> <td> <p> $96.6m </p> </td> <td> <p> <a href="http://www.clinica.co.uk/marketsector/ivds/Prenatal-test-maker-grabs-biggest-VC-bucks-to-date-342723?autnID=/contentstore/clinica/codex/a8ffd263-b27d-11e2-81a2-85260ee98534.xml">May</a> </p> </td> </tr> <tr> <td> <p> Proteus Digital Health (Redwood City, CA, US) </p> </td> <td> <p> Digital medicine </p> </td> <td> <p> Proteus has CE marked and FDA-cleared its range of wearable and investible sensor devices. These sensors are coupled with existing pharmaceutical treatments to communicate, via a digital health feedback system, vital information about an individual's medication taking behaviour and how their body is responding. </p> </td> <td> <p> Medtronic, Novartis, Carlyle, Essex Woodlands, Kaiser Permanente, Otsuka, Oracle, ON Semiconductor and other investors </p> </td> <td> <p> $62.5m </p> </td> <td> <p> Series F </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> BioFire Diagnostics (Salt Lake City, UT, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> BioFire's FilmArray is a FDA-cleared multiplex PCR test that integrates sample prep, amplification, detection and analysis into one system. The firm has developed a respiratory panel to detect up to 20 viral and bacterial pathogens. </p> </td> <td> <p> Athyrium Opportunities Fund </p> </td> <td> <p> $20m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Channel Medsystems (San Francisco, CA, US) </p> </td> <td> <p> Women's health </p> </td> <td> <p> Channel Medsystems is developing a cryogen-based global endometrial ablation technology, used to treat excessive menstrual bleeding. </p> </td> <td> <p> Boston Scientific, InCube Ventures, Aperture ventures, Scientific Health Development II and STCM Ventures </p> </td> <td> <p> $9.7m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> STAT-Diagnostica (Barcelona, Spain) </p> </td> <td> <p> IVD </p> </td> <td> <p> STAT-Diagnostica specialises in near-patient testing diagnostic systems that combine molecular and immunoassay techniques in a single device. The first clinical applications will be directed at infectious disease detection, antibiotic resistance determination and detection of biomarkers in critically ill patients.The EU launch of the first products expected in 2015. </p> </td> <td> <p> Kurma Life Sciences Partners, Idinvest, Boehringer Ingelheim Venture Fund, Caixa Capital Risc, Ysios Capital and Axis </p> </td> <td> <p> $22.1m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Ocon Medical (Israel) </p> </td> <td> <p> Women's health </p> </td> <td> <p> Ocon's IUB (ntra Uterine Ball) device is said to be the first and only three dimensional and spherical contraceptive intra uterine device. The first product is currently in clinical trials and expected to be CE marked in 2013; also in development are drug- and hormone-eluting IUBs. </p> </td> <td> <p> Pontifax, Docor International Management </p> </td> <td> <p> NIS6m ($1.6m) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Cardio3 Biosciences (Mont-Saint-Guibert, Belgium) </p> </td> <td> <p> Regenerative medicine </p> </td> <td> <p> Cardio3's C-Cure product is a cell-based therapy for cardiac diseases. The product, currently in Phase III trials, uses bone marrow cells that are reprogrammed into cardiopoietic cells. These cells are then injectted into the patient's heart to help regenerate new heart tissue and repair damaged heart muscle </p> </td> <td> <p> Mayo Clinic, Tolefi, SRIW Techno SA, Umbrela Investments, Grifols, HUNZA Ventures II, Life Sciences Research Partners, Avion and other private investors </p> <p></td> <td> <p> &euro;19m ($24.7m) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> &euro;51.8m </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> SpineVision (Antony, France) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> SpineVision develops and commercialises implants and instrumentation for spinal surgery. </p> </td> <td> <p> Omega Funds and others </p> </td> <td> <p> $10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Nuclea Biotechnologies (Pittsfield, MA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Nuclea is focused on discovering proprietary biomarkers and developing diagnostic and prognostic tests for colon, stomach, leukemia, lung and prostate cancers. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $4.2m </p> </td> <td> <p> Series D </p> </td> <td> <p> $40.3m </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Lanx (Broomfield, CO, US) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> Lanx has developed a line of minimally-invasive spinal fusion systems, including the Timberline lateral fusion system and the Aspen MIS fusion system. </p> </td> <td> <p> Credit Suisse Asset Management, Chicago Growth Partners, Goldman Sachs Private Equity Opportunities Fund, Noro-Moseley Parteners, Oakwood Medical Investors </p> </td> <td> <p> $15m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Daktari Diagnostics (Cambridge, MA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Daktari CD4 is a CD4 cell counting system for HIV testing. It is designed to be portable and robust enough for use anywhere, from the doctor's office to the most remote settings. The system is currently being trialled in Africa. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $7m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Thermedical (Waltham, MA, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> Thermedical has developed SERF saline-enhanced radiofrequency ablation technology for ablating soft tissue during percutaneous, laparoscopic and intraoperative surgical procedures. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5m </p> </td> <td> <p> Series A2 </p> </td> <td> <p> $7m </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> BPL Medical Technologies (India) </p> </td> <td> <p> Medical equipment </p> </td> <td> <p> BPL makes a diverse range of equipment including electrocardiographs, defibrillators, patient monitors, oxygenators and ultrasound scanners. </p> </td> <td> <p> Goldman Sachs </p> </td> <td> <p> Rs1.1bn ($20m) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Castle Bioscences (Houston, TX, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Castle develops molecular diagnostic tests for rare cancers. It currently has five products available, including for uveal melanoma, thymoma, and brain cancer. </p> </td> <td> <p> Mountain Group Capital and Affiliates, Long Fellow Venture Partners I, State of Texas Emerging Technology Fund. </p> </td> <td> <p> $1.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Phagenesis (Manchester, UK) </p> </td> <td> <p> ENT </p> </td> <td> <p> Phagenesis has a CE marked electrostimulation treatment, Phagenyx, for the swallowing disorder dysphagia. The treatment electrically stimulates the oropharynx to improve the patient's ability to swallow. </p> </td> <td> <p> Inventages Venture Capital and other private investors </p> </td> <td> <p> $17m </p> </td> <td> <p> Expanded series B </p> </td> <td> <p> $20m </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Advanced Accelerator Applications (Saint-Genis-Pouilly, France) </p> </td> <td> <p> Molecular nuclear medicine </p> </td> <td> <p> AAA produces and sells PET (positron emission tomogrpahy) and SPECT (single photon emission computed tomography) for treating various diseases including cancer. </p> </td> <td> <p> Seventure Partners and other investors </p> </td> <td> <p> &euro;4.8m ($6.2m) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> &euro;61m </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Inova Labs (Austin, TX, US) </p> </td> <td> <p> Respiratory disorders </p> </td> <td> <p> Inova has developed the LifeChoice portable oxygen concentrator. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $12m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Agea Medical (Redwood City, CA, US) </p> </td> <td> <p> Women's health </p> </td> <td> <p> Agea has developed a system that uses vapor to abalte uterine cavity tissue, thereby treating excessive menstrual bleeding. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Linkage Biosciences (San Francisco, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Likage specialises in human leukocyte antigen (HLA) typing and associated products. It's LinkSeq HLA product line uses proprietary software and chemistry together with real-time PCR instrument to achieve faster results. HLA testing is used in solid organ and hematopoetic stem cell transplantation as well as pharmacogenomic and autoimmune disease testing. </p> </td> <td> <p> Fisher Capital, Greenhouse Capital Partners and Big kSky Partners </p> </td> <td> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Microvisk (North Wales, UK) </p> </td> <td> <p> IVD </p> </td> <td> <p> Microvisk has developed a home blood testing device for patients to monitor and manage their use of anti-coagulant drugs. </p> </td> <td> <p> Porton Capital, Oxford Technology Fund, Advantage Growth Fund, and other private investors </p> </td> <td> <p> &pound;2m ($3m) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> BacterioScan (St Louis, MO, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Bacterioscan has developed a benchtop system for use by hospital labs to test for urinary tract infections with a result turnaround time fo under three hours. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> Mercator Medsystems (San Leandro, CA, US) </p> </td> <td> <p> Drug delivery </p> </td> <td> <p> Mercator develops micro -infusion catheters for site-specific drug delivery. The company is initiating EU, US and Australian sales of its CE-marked and FDA 510(k)-cleared Bullfrog and Cricket systems. </p> </td> <td> <p> Volcano Capital, Crocker Capital, Aphelion Capital, Windy City Inc, SET Technology Gmbh </p> </td> <td> <p> $6.5m </p> </td> <td> <p> Series B </p> </td> <td> <p> $18.5m </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> ZSX Medical (King of Prussia, PA, US) </p> </td> <td> <p> Women's health </p> </td> <td> <p> ZSX has developed the Zip Stitch surgical closure system, a bioabsorbable device to close wounds from laparoscopic hysterectomies, enabling faster healing and improved outcomes. </p> </td> <td> <p> Ben Franklin Technology Partners and other investors </p> </td> <td> <p> $1.4m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> May </p> </td> </tr> <tr> <td> <p> <b>JUNE</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Horizon Discovery (Cambridge, UK) </p> </td> <td> <p> IVD </p> </td> <td> <p> Horizon offers genetically-defined cell lines as well as reporter gene cell-based assay kits, used in personalised medicine. The firm also offers contract assay development as well as target identification and validation services. </p> </td> <td> <p> DFJ Esprit, MVM Life Science, Roche Venture Fund, Providence Investment Company, Wren Capital, Calculus Capital, University of Cambridge Enterprise Fund and private investors </p> </td> <td> <p> &pound;6.9m ($10.5m) </p> </td> <td> <p> Series C-tranche </p> </td> <td> <p> Undisclosed (but total series C is $29.1m) </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> DiaTech Oncology (Nashville, TN, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> DiaTech offers patient-speciic cancer testing services. Its MiCK assay (or Correct Chemo) is a predictive test to help oncologists determine which is the best treatment plan for specific patients. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $18m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Nanospectra Biosciences (Houston, TX, US) </p> </td> <td> <p> Nanomedicine </p> </td> <td> <p> Nanospectra's Aurolase therapy is a nanoparticle-based technology for treating cancer. The nanoparticles are infused intravenously so that they accumulate in the tumour and then are heated by an infrared laser source, killing the cancer cells. The therapy is in a pilot trial. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $1.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $16m (of which is public funding) </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> WaveTec Vision (Aliso Viejo, CA, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Wavetec is developing the ORA system, a diagnostic device tha provides continuous measurements of the patient's eye during cataract surgery. This allows for more precise measurement to help improve refractive outcomes. </p> </td> <td> <p> Accuitive Medical Ventures, De Novo Ventures, Versant Ventures, Burrill &amp; Company, Gund Investment and other investors </p> </td> <td> <p> $11m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Diagnoplex (Lausanne, Switzerland) </p> </td> <td> <p> IVD </p> </td> <td> <p> Colox is Diagnoplex's noninvasive blood-based test for the early detection of colon cancer. </p> </td> <td> <p> Debiopharm, Neomed, Initiative Capital Romandie </p> </td> <td> <p> CHF1.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> TVA Medical (Austin, TX, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> TVA is developing a minimally invasive catheter-based system designed for creating an arterio-venous fistula to deliver hemodialysis to patients suffernig kidney failure. </p> </td> <td> <p> S3 Venture, TriStar Technology and Sante Ventures </p> </td> <td> <p> $9.5m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Emperra E-Health Technologies (Potsdam, Germany) </p> </td> <td> <p> Telemedicine </p> </td> <td> <p> Emperra has developed ESYSTA, a web-based closed-loop management system for Type 1 and 2 diabetes patients. The system comprise both hardware and software, including a proprietary insulin pen. </p> </td> <td> <p> Peppermint VenturePartners, GoodVent Beteiligungsmanagement, BC Bradenburg Capital, S-UBG, MBG </p> </td> <td> <p> &euro;2.6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Mobisante (Redmond, WA, US) </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> Mobisante specialises in smartphone and table-based ultrasound imaging systems. </p> </td> <td> <p> WRF Capital, W Fund and angel investrs </p> </td> <td> <p> $4.2m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Acutus Medical (San Diego, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Acutus has developed a 3D cardiac electrical mapping system to identify areas of the heart that requires ablation to treat atrial fibrillation. </p> </td> <td> <p> Orbimed, Index Ventures, Advent Ventures </p> </td> <td> <p> $21.6m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> EBS Technologies (Kleinmachnow, Germany) </p> </td> <td> <p> Neurology </p> </td> <td> <p> EBS' Next Wave deep brain stimulation device is designed to reverse vision impairment caused by brain injury and stroke. </p> </td> <td> <p> Earlybird Venture Capital, ILB, High-Tech Grunderfonds </p> </td> <td> <p> $3.9m </p> </td> <td> <p> Series B </p> </td> <td> <p> $8.7m </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> NeuroTronik (Chapel Hill, NC, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> NeuroTronik is developing a neuromodulation device that would treat acute heart failure syndrome patients with worsening symptoms. </p> </td> <td> <p> Hatteras Venture PArtners and other investors </p> </td> <td> <p> $13.1m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Acerde (Clermont-Ferrand, France) </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> Accerde manufactures rotating anodes for X-ray tubes. </p> </td> <td> <p> Truffle Capital </p> </td> <td> <p> &euro;1.2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> &euro;5.4m </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Lantos Technologies (Cambridge, MA, US) </p> </td> <td> <p> Imaging </p> </td> <td> <p> Lantos' 3D ear canal scanning system is US 510(k)-cleared. It is used to help with the fitting of hearing aids. </p> </td> <td> <p> Catalyst Health Ventures, Excel Venture Management, Omega Funds, Mass Medical Angels </p> </td> <td> <p> $1.45m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Valkee (Helsinki, Finland) </p> </td> <td> <p> Neurology </p> </td> <td> <p> Valkee has developed a headset device that channels bright light via the ear canals into the brain, thereby reducing symptoms of seasonal affective disorder. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $9.7m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Ocular Therapeutix (Bedford, MA, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Ocular has developed drug-eluting punctum plugs for treating glaucoma and post-operative inflammation and pain. It has also developed injectable drug depots for back of the eye diseases, and a sealant, ReSure, for use in cataract surgery. </p> </td> <td> <p> Baxter Ventures, Ascension Health Ventures, Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta </p> </td> <td> <p> $8.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> HemoSonics (Carlottesviille, VA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Hemosonics' point of care analysers are designed to detect life-threatening bleeding and blood clots, during surgical procedures. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $1.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Exosome Diagnostics (New York, NY, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Exosome specialises in exosome technology to develop biofluid-based assays. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $6.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Veniti (St Louis, MO, US) </p> </td> <td> <p> Vascular </p> </td> <td> <p> Veniti is developing three venous disease treatments: a radiofrequency-based varicose vein treatment, a vena cava blood clot filter and a venous stent. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $9.7m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Mirabilis Medica (Seattle, WA, US) </p> </td> <td> <p> Women's health </p> </td> <td> <p> Mirabilis is developing a noninvasive system for treating uterine fibroids, using high-intensity focused ultrasound </p> </td> <td> <p> GSR Ventures, vSpring Capital, Charter Lifesciences, Arboretum Ventures, Split Rock Partners, Dow Venture Capital </p> </td> <td> <p> $7m </p> </td> <td> <p> Part of Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Medivo (New York, NY, US) </p> </td> <td> <p> Healthcare IT </p> </td> <td> <p> Medivo's cloud-based, data analytics platform connects doctors, consumers and clinical labs to improve patient management and monitoring. </p> </td> <td> <p> Merck Global Health Innovation Fund, Safeguard Scientifics, MentorTech Ventures </p> </td> <td> <p> $15m </p> </td> <td> <p> Series B </p> </td> <td> <p> $22m </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Minimally Invasive Devices (Columbus, OH, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> MID's flagship product is the FloShield laparoscopic vision system, designed to prevent the optics being obscured during laparascopic surgery. </p> </td> <td> <p> Radius Venture, Charter Life Scinces, Canaan Partners </p> </td> <td> <p> $2.5m </p> </td> <td> <p> Series B-2 </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Vertos Medical (Aliso Viejo, CA, US) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> Vertos' 510(k)-cleared <i>mild</i> procedure is an outpatient procedure that helps patients with lumbar spinal stenosis to stand longer and walk further with less pain </p> </td> <td> <p> Pitango Venture Capitl, ONSET Ventures, CHL Medical Partners, Foundation Medical Partners, Mercury Fund, Aweida Venture Partners </p> </td> <td> <p> $23m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Amaranth Medical (Mountain View, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Amaranth specialises in bioresorbabel cardiovascular stents. </p> </td> <td> <p> Bio*One Capital, Charter Life Sciences, Philip Capital and other investors </p> </td> <td> <p> $25m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> ForSight Vision5 (Menlo Park, CA, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> ForSight is developing ophthalmic devices. </p> </td> <td> <p> Technology Partners, Delphi Ventures, Morganthaler Ventures, Versant Ventures </p> </td> <td> <p> $9.3m </p> </td> <td> <p> Series B-1 </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> NuMedii (Palo Alto, CA, US) </p> </td> <td> <p> Bioinformatics </p> </td> <td> <p> NuMedii's technology leverages the vast amounts of &quot;Big Data&quot; correlating disease information with drug data to predict which drugs will be most effective in treating a particular disease. </p> </td> <td> <p> Claremont Creek Ventures, Lightspeed Venture Partners, Life Science Angels and others </p> </td> <td> <p> $3.5m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> ALung Technologies (Pittsburgh, PA, US) </p> </td> <td> <p> Critical care </p> </td> <td> <p> ALung's lead product is the CE-marked HemoLung Respiratory Assist device for patients with acute respiratory failure. The HemoLung is designed to perform Respiratory Dialysis, which removes carbon dioxide from a patient's body while infusing it with oxygen. This helps to eliminate the need for patients to breathe through a tube or ventilator. </p> </td> <td> <p> Eagle Ventures, Birchmere Ventures and others </p> </td> <td> <p> $9.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Mevion Medical Systems (Littleton, MA, US) </p> </td> <td> <p> Cancer therapy </p> </td> <td> <p> Mevion specialises in single-room proton therapy for cancer. Its S250 system is US FDA-cleared and is designed with a footprint of a modern X-ray radiotehrapy device, significantly smaller than convention proton therapy systems. </p> </td> <td> <p> Caxton Health Life Sciences, ProQuest Investments, Venrock, CHL Medical Partners, Life Sciences Alternative Funding </p> </td> <td> <p> $55m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Vital Therapies (San Diego, CA, US) </p> </td> <td> <p> Renegerative medicine </p> </td> <td> <p> Vital Therapies is conducting clinical trials of ELAD, a human cell-based bioartificial liver. It is designed to stabilize liver function in patients with acute organ failure, hepatitis B and alcohol hepatitis. It acts as bridge-to-transplant or enables liver recovery. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $22.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> More than $150m </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Actus Medical (San Diego, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Actus is developing a minimally invasive, realtime 3D Cardiac Chamber Imaging and Dipole Density Mapping system to identify the sources that cause heart arrhythmias, including atrial fibrillation. </p> </td> <td> <p> OrbiMed Ventures, Index Ventures, Advent Ventures </p> </td> <td> <p> $21m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Middle Peak Medical (Palo Alto, CA, US and Munich, Germany) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Middle Peak is developing a novel technology for mitral valve disease. </p> </td> <td> <p> Wellington Partners, Seventure Partners, High-Tech Grunderfonds Management </p> </td> <td> <p> $8.5m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Aviir (Irvine, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Avvir has developed the MIRISK VP test for assessing a patient's risk of experiencing future cardiac events like heart attacks </p> </td> <td> <p> Partners &amp; Partners, Merck Global HEalth Innovation Fund, Bay City Capital, Aberdare Ventures, New Leaf Venture Partners </p> </td> <td> <p> $10m </p> </td> <td> <p> Third tranche of a $30m round </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Veracyte (South San Francisco, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Veracyte's first product is the Afirma Thyroid FNA Analysis, a gene expression test to help reduce unnecessary surgeries as part of thyroid cancer diagnosis. </p> </td> <td> <p> GE Ventures, Domain Associates, Kleiner Perkins Caulfield &amp; Byers, TPG Biotech, Versant Ventures </p> </td> <td> <p> $28m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> Sonendo (Laguna Hills, CA, US) </p> </td> <td> <p> Dental surgery </p> </td> <td> <p> Sonendo's products targets the endodontic market. Its products, like the Multisonic Ultracleaning System, is based on the company's Sound Science technology which enable root canals to be simultaneously cleaned in five minutes. </p> </td> <td> <p> OrbiMed Advisors, Themes Investment Partners, Fjord Ventures, NeoMed Management </p> </td> <td> <p> $18m </p> </td> <td> <p> Second tranche of a $27m round </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> June </p> </td> </tr> <tr> <td> <p> <b>JULY</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> NeuroPace (Mountain View, CA, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> NeuroPace is trialing its RNS system, an implantable devices that delivers responsive neurostimulation to the brain, for treating epilepsy. </p> </td> <td> <p> New Enterprise Associates, InterWest Partners, J&amp;J Development, Kleiner Perkins Caufield &amp; Byers, MedVenture Associates, Technology Venture Partners and Domain Associates </p> </td> <td> <p> $18m </p> </td> <td> <p> Part of a larger $50m round </p> </td> <td> <p> $180m </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> GeneCentric Diagnostics (Durham, NC, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> The Lung Subtype Platform by GeneCentric is a diagnostic that stratifies lung cancer patients into subtypes based on gene profiling of the tumor sample, enabling physicians to determine the best therapy for the patient, including newer targeted therapies. Its second product under development is a diagnostic to identify cancer patients who may respond to anti-angiogenesis inhibitors. </p> </td> <td> <p> Hatteras Venture Partners </p> </td> <td> <p> $2.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Crossject (Paris, France) </p> </td> <td> <p> Drug delivery </p> </td> <td> <p> Crossject specialises in needle-free injection systems. It has three products based on its Zeneo platform, which are undergoing bioequivalence studies. </p> </td> <td> <p> A Plus Finance, Sofimac Partners, Gemmes Venture, and private investors </p> </td> <td> <p> $6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> HeadSense (Netanya, Israel) </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> HeadSense is developing a noninvasive intracranial pressure monitor. The device would be used for diagnosis and monitoring of patients suffering from head trauma, strokes and other neurological conditions. </p> </td> <td> <p> Pontifax, GE Ventures, Everett Partners, JuMaJo </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> MitrAssist (MIsgav, Israel) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> MitrAssist's mitral regurgitation treatment is not designed to replace or repair the defective mitral valve. Instead, the implant developed by the company is placed on top of the natural mitral valve to support its function. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $1m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Gamma Medica (Salem, NH, US) </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> Gamma is commercialising the LumaGEM digital molecular breast imaging (MBI) system together with the LumaGUIDE MBI-guided biopsy module. </p> </td> <td> <p> Psilos Group Managers </p> </td> <td> <p> $16m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Cartiva (Alpharetta, GA, US) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> Cartiva is conducting a pivotal trial of its synthetic cartilage implant designed to replace damaged cartilage in the great toe. The implant is meant to preserve motion and be an alternative to fusion. </p> </td> <td> <p> New Enterprise Associates </p> </td> <td> <p> $4.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Adaptive Biotechnologies (Seattle, WA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> The immunoSEQ is a suite of next-generation immune sequencing assays that allow researchers to view and analyse the T and B cells of the adaptive immune system. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Oss-Q (Stockhom, Sweden) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> Oss-Q is initiating a clinical trial of its OssDsign Cranio PSI, an implant for skull reconstruction. </p> </td> <td> <p> Karolinska Development </p> </td> <td> <p> SEK6.8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> CVRx (Minneapolis, MN, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> The Barostim <i>neo</i> is an implantable, carotid artery-stimulating system. It is CE marked for treating hypertension, but not approved yet in the US. It is also being trialled for treating heart failure. </p> </td> <td> <p> New Enterprise Associates, J&amp;J Development, BBT Fund, SightLine Partners </p> </td> <td> <p> $29.6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Sensimed (Lausanne, Switzerland) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> The Sensimed Triggerfish is a contact lens monitor that continuously measure intraocular pressure in glaucoma patients. </p> </td> <td> <p> Vertex Healthcare Venture Partner, Wellington Partners, Agate Medical Investments, Vinci Capital/Renaissance PME , and others </p> </td> <td> <p> CHF8m </p> </td> <td> <p> Second tranche of Series C </p> </td> <td> <p> CHF51.6m </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> PathoQuest (Paris, France) </p> </td> <td> <p> IVD </p> </td> <td> <p> PathoQuest is developing a next-generation sequencing technology for infectious diseaes. </p> </td> <td> <p> Idinvest, Aurinvest, Kurma Life Science Partners </p> </td> <td> <p> E3.8bn </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> InterValve (Minneapolis, MN, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> InterValve's V8 valvuloplasty balloon catheter is FDA-cleared for used in stanalone balloon aortic valvuloplasty and for pre-dilation during transcather aortic valve implantation. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2.6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Lantos Technologies (Wakefield, MA, US) </p> </td> <td> <p> Imaging </p> </td> <td> <p> Lantos is developing an ultrasound-based, 3D ear canal-mapping device. It eliminates the need for silicone moulding of the canal. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5.1m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> ViaCyte (San Diego, CA, US) </p> </td> <td> <p> Regenerative medicine </p> </td> <td> <p> The VC-01 is a stem cell-based therapy targeting type 1 diabetic patient. The stem cells replace the pancreatic cells destroyed in type 1 diabetes and are enclosed by a semi-permeable screen that protects the cells from the immune system. </p> </td> <td> <p> J&amp;J Development, Sanderling Ventures, Asset Management and others </p> </td> <td> <p> $10.6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Sequenta (South San Francisco, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> The next-generation sequencing-based ClonoSight Test uses Sequenta's LymphoSight technology, an immune cell receptor focused platform to predict a patient's risk of post treatment relapse and to guide treatment. </p> </td> <td> <p> Foresite Capital Management, MDV, Idex Ventures and more </p> </td> <td> <p> $20m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Claret Medical (Santa Rosa, CA, US) </p> </td> <td> <p> Neurovascular </p> </td> <td> <p> Claret's CE-marked Montage Dual Filter system is used to capture emboli that might be loosened during transcatheter aortic valve implantation procedures and if it reaches the brain, cause a stroke. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $3.6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Blaze Biosciences (Seattle, WA, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> Tumor Paint is a surgical tool that visually distinguishes solid tumor cells from healthy cells. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $8.1m </p> </td> <td> <p> First tranche of Series B </p> </td> <td> <p> $16.6m </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> EyeNetra (Somerville, MA, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> ENTRA -G is a diagnostic adapter that attaches to a smartphone and enables the user to carry out a refractive eye test by themselves without having to go to an optician. The mobile diagnostic measures near- and far-sightedness as well as astigmatism. </p> </td> <td> <p> Khosla Impact </p> </td> <td> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> SynGen (Sacramento, CA, US) </p> </td> <td> <p> Regenerative medicine </p> </td> <td> <p> SynGen specialises in advanced cell separation tools. Its SynGenX-1000 Platform for cord blood processing was cleared in July 2013 by the US FDA. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> X2 Biosystems (Seattle, WA, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> X2 is developing sensors for sports brain injuries. It has developed a concussion detection device that is the size of a postage stamp and worn by atheletes that sends impact metrics to a web-based database. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $3.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Arch Therapeutics (Cambridge, MA, US) </p> </td> <td> <p> Regenerative medicine </p> </td> <td> <p> Arch is targeting the woundcare market with AC5, a synthetic peptide that has naturally occuring amino acies. The product is used during surgery to provide a barrier to stop wounds from bleeding or leaking other bodily fluids. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $7.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Renovis Surgical (Redlands, CA, US) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> Renovis is developing surgical orthopaedic devices </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> TB Biosciences (Bethlehem, PA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> TB Biosciences is developing an affordable, easy-to-use rapid point-of-care test to detect active tuberculosis. The aim is for the test to replace current sputum smear assessments. </p> </td> <td> <p> Originate Ventures, Ben Franklin Technology Partners and the NYU Innovation Venture Fund </p> </td> <td> <p> $1.5m </p> </td> <td> <p> Series A </p> </td> <td> <p> Over $2.5m (including grants) </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> ViVex Biomedical (Marietta, GA, US) </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> ViVex is developing a stem cell therapy, MIAMI, for treating spinal cord injuries, orthopedic injuries and traumatic wounds. It is also developing polymer implants for spinal surgery - the implants have a mimetic surface that stimulate new cell growth. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2.2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> SynapDx (Lexington, MA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> SynapDx is developing a blood- based test for early detection fo Autism Spectrum Disorders. </p> </td> <td> <p> Google Ventures, Foundation Medical Partners, North Bridge Venture Partners and General Catalyst Partners </p> </td> <td> <p> $15.4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> KellBenx (Long Island, NY, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> KellBenx is developing a blood-based prenatal test to detect genetic abnormalities in foetuses. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> JenaValve (Munich, Germany and Wilmington, DE, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> JenaValve specialises in transcatheter aortic valve implantation technologies. It is already commercialising a transapical TAVI product and initiating a clinical study on a transfemoral version. </p> </td> <td> <p> Gimv, Legend Capital, Omega Funds, Edmond de Rothschild Investment Partners, Atlas Venture Fund, NeoMed Managemenet, VI Partners, Sunstone Capital </p> </td> <td> <p> $62.5m </p> </td> <td> <p> Series C </p> </td> <td> <p> $105.3m </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Soluble Systems (Newport News, VA, US) </p> </td> <td> <p> Wound care </p> </td> <td> <p> Soluble systems has two FDA-cleared products: Theraskin, an artificial skin graft, and TheraGuaze, a moisture-retaining dressing </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $3.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Avantis Medical Systems (Sunnyvale, CA, US) </p> </td> <td> <p> Surgery/Imaging </p> </td> <td> <p> Avantis has developed the Third Eye Retroscope, a device that offers an extra view to a colonoscope. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $3m </p> </td> <td> <p> Part of larger series D </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Caymus Medical (San Juan Capistrano, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Caymus is in stealth mode, but it has patents for technologies relating to various minimally-invasive interventional cardiovascular applications. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $3.9m </p> </td> <td> <p> Part of larger $10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> ReVision Optics (Lake Forest, CA, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Revision's Raindrop Near Vision Inlay is a microscopic hydrogel inlay designed to correct presbyopia, thereby reducing or eliminating the need for reading glasses. </p> </td> <td> <p> Canaan Partners, ProQuest Investments, InterWest Partners, Domain Associates, J&amp;J Development Corporation, RusnanoMedInvest </p> </td> <td> <p> $55m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> Bina Technologies (Redwood City, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> BINA has developed a platform for delivering &quot;fast, accurate and scalable genomic analysis&quot; . The data will drive personalised medicine. </p> </td> <td> <p> Columbus Nova Technology Partners, AME Cloud Ventures </p> </td> <td> <p> $1.75m </p> </td> <td> <p> Part of a bigger $8m Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> ConforMIS (Bedford, MA, US) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> ConforMIS specialises in manufacturing personalised, patient-specific knee implants and instrumentation. </p> </td> <td> <p> AGC Equity Partners, Axel Johnson, Aeris Capital, sovereign-wealth funds and other global investors </p> </td> <td> <p> $167.7m </p> </td> <td> <p> Series E </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> NeuWave Medical (Madison, WI, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> NeuWave has developed minimally-invasive soft tissue ablation systems </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $19m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> July </p> </td> </tr> <tr> <td> <p> <b>AUGUST</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Ablative Solutions (Menlo Park, CA, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> Ablative is developing a renal denervation technology for managing hypertension. The system delivers the energy directly to the renal nerves themselves. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2.7m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> NxThera (Maple Grove, MN, US) </p> </td> <td> <p> Urology </p> </td> <td> <p> NxThera has developed Rezum, a water vapor endourology treatment for benign prostatic hyperplasia. The technology is already CE marked. </p> </td> <td> <p> Arboretum Ventures, Aberdare Ventures, GDN Holdings, American Medical Systems, among others </p> </td> <td> <p> $18.2m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> MicroTransponder (Dallas, TX, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> MicroTransponder has developed a clinical trial-stage vagal nerve stimulation platform for treating stroke, tinnitus and chronic pain. The Vivistim system is designed to treat stroke patients with upper-limb deficit following thier stroke, and the Serenity system is a paired tone-stimulation tereatment for tinnitus. </p> </td> <td> <p> Green Park &amp; Gold Ventures, UT Horizon Fund, angel investors and others </p> </td> <td> <p> $3.4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> LensAR (Orlando, FL, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> The LensAR laser system is CE-marked cleared by the US FDA for creating corneal and arcuate incisions during cataract surgery and for anterior capsulotomy. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> DermTech (San Diego, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> DermTEch is a skinc cancer diagnostic company. It is developing qPCR assays for skin samples collected noninvasively using adhesive tape biopsy methods. </p> </td> <td> <p> Jacobs Investment Company and other investors </p> </td> <td> <p> $5.6m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> TissueTech (Miami, FL, US) </p> </td> <td> <p> Regenerative medicine </p> </td> <td> <p> TissueTech makes amniotic membrane and umbilical cord-based products. It markets the products for ocular surface diseases through its Bio-Tissue subsidiary, and for musculoskeletal conditions and wound care through its Amniox Medical subsidiary. </p> </td> <td> <p> Ballast Point Ventures, River Cities Capital Funds and other investors </p> </td> <td> <p> $10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> Ivantis (Irvine, CA, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Ivantis has developed the Hydrus microstent for lowering eye pressure in patients with glaucoma. </p> </td> <td> <p> EDBI, Ascension Health Ventures, New Enterprise Associates, Delphi Ventures, MemorialCare Innovation Fund </p> </td> <td> <p> $5m </p> </td> <td> <p> Part of bigger $32.5m series B </p> </td> <td> <p> $68.5m </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> SomaLogic (Boulder, CO, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> SomaLogic has developed the SOMAscan protein biomarker discovery platform. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> Acutus Medical (San Diego, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Acutus is developing a minimally invasive imaging system for 3D, real-time visualization and detection of heart arrhythmias. </p> </td> <td> <p> Orbimed, GE Ventures, Index Ventures, Advent Life Sciences and others </p> </td> <td> <p> $6m </p> </td> <td> <p> Part of a bigger $28m series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> BioDirection (Tucson, AZ, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> BioDirection's Tbit testing platform allows point-of-care brain injury screening and monitoring, using a drop of blood, to separate minor head injuries from traumatic head injury. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $3.95m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> Applied Proteomics (San Diego, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Applied Protemoics is commercialising multiplex protein-based diagnostics for detecting early-stage disease. Its first test is for precursors to colorectal cancer. </p> </td> <td> <p> Genting Berhad and others </p> </td> <td> <p> $28m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> Freedom Meditech (San Diego, CA, US) </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> Freedom's ClearPath DS-120 is a US FDA-cleared device that scans the eye to detect signs of diabetes. The firm has developed also I-SugarX, a noninvasive glucose meter that works by holding a small device in front of the eye. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> SetPoint Medical (Valencia, CA, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> SetPoint is developing a vagal nerve stimulation device for modulating the body's natural inflammatory reflex. The initial target market is rheumatoid arthritis. </p> </td> <td> <p> Action Potential Venture Capital, Covidien Ventures, Boston Scientific and others </p> </td> <td> <p> $27m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> Cardiva (Sunnyvale, CA, US) </p> </td> <td> <p> Minimally invasive surgery </p> </td> <td> <p> Cardiva specialises in vascular closure. Its CE-marked Vascade extravascular closure device is designed to close the opening left in the artery following an interventional procedure, without the need for an intravascular compoentn. </p> </td> <td> <p> PTV Sciences, Galen Partners, Sycamore Ventures, Amkey Ventures LLC and TriVentures </p> <p><p></td> <td> <p> $3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> Cernostics (Danville, PA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Cernostics has developed a molecular diagnostic test, based on its TissueCipher Pathology approach, to predict the likelihood of a Barrett's oesophagus becoming oesophageal cancer. </p> </td> <td> <p> Ben Franklin Technology Partners and others </p> </td> <td> <p> $1.4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> Endomagnetics (Cambridge, UK) </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> Endomagnetics applies advanced magnetic sensing technology and nanotechnology to develop devices for breast cancer management. Its SentiMag ultrasensitive handeheld probe detects the location of injected Sienna+ tracer material, eliminating the need for short-life radioactive alternatives in use today. </p> </td> <td> <p> New Wave Ventures, Sarum Capital, UCL Business, Sussex Place Ventures. </p> </td> <td> <p> &pound;2.1m ($3.2m) </p> </td> <td> <p> Series B </p> </td> <td> <p> &pound;4.6m </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> Xlumena (Mountain View, CA, US) </p> </td> <td> <p> Minimally invasive surgery </p> </td> <td> <p> Xlumena specialises in endoscopic device. Its latest device is the Axios stent and delivery system for treating pancreatic cysts. </p> </td> <td> <p> Aperture Venture Partners, Western Technology Investment, Prism Ventures, Charter Life Sciences, Ascent Biomedical Ventures and others </p> </td> <td> <p> $4.8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> Exosome Diagnostics (New York, NY, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Exosome is developing biofluid-based molecular diagnostic tests for use in personalised medicine </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $7m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> TransEnterix (Research Triangle Park, NC, US) </p> </td> <td> <p> Minimally invasive surgery </p> </td> <td> <p> TransEntrix has developed the US FDA-cleared Spider surgical platform for laparoscopic procedures, and the SurgiBOT, a bedside, robotic surgical system. </p> </td> <td> <p> Asiling Capital, Parish Capital Advisors, SV Life Sciences, Synergy Life Science Partners, Intersouth Partners and Quaker Partners </p> </td> <td> <p> $2.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> Infraredx (Burlington, MA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Infraredx's CE-marked and US-approved TVC (true vessel characterization) imaing system is designed to detect lipid core plaques, which complicate stenting procedures and linked with adverse events. </p> </td> <td> <p> Nipro, Sanderling Ventures, and other investors </p> </td> <td> <p> $25m </p> </td> <td> <p> Part of a bigger $75m series E </p> </td> <td> <p> $175m </p> </td> <td> <p> August </p> </td> </tr> <tr> <td> <p> <b>SEPTEMBER</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Active Implants (Memphis, TN, US) </p> </td> <td> <p> Orthopaedics </p> </td> <td> <p> Active implants specialises in cushion-bearing hip and knee implants, including the NUsurface menisucus implant and the Tribofit hip system. </p> </td> <td> <p> View Capital RIA, River Street Management, and others </p> </td> <td> <p> $8.7m </p> </td> <td> <p> Part of a larger $26m round </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> ALung Technologies (Pittsburgh, PA, US) </p> </td> <td> <p> Respiratory disorders </p> </td> <td> <p> Alung has developed the Hemolung RAS that provides Respiratory Dialysis, a minimally invasive form of extracorporeal carbon dioxide removal. </p> </td> <td> <p> Allos Ventures, West Capital Partners, Birchmere Ventures, BlueTree Capital Group, PLSG Accelerator Fund, Smithfield Trust Company and private investors </p> </td> <td> <p> $15.8m </p> </td> <td> <p> Series B-1 </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> EndoTools Therapeutics (Gosselies, Belgium) </p> </td> <td> <p> Minimally invasive surgery </p> </td> <td> <p> EndoTools has several CE-marked advanced endoscopic instruments including Endomina, a device that can perform complex movements and allow surgeons to use multiple instruments when operating. </p> </td> <td> <p> Private investors </p> </td> <td> <p> $3.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> Cequr (Horw,(Switzerland and Marlborough, MA, US) </p> </td> <td> <p> Drug delivery </p> </td> <td> <p> Cequr has developed PaQ, a CE-marked, automated insulin delivery device for Type 2 diabetics. The device is wearable for 3 days continuous </p> </td> <td> <p> BMC Ventures, Endeavour Vision, Schroder &amp; Co Bank, Venture Incubator and private investors </p> </td> <td> <p> $27m </p> </td> <td> <p> Series B </p> </td> <td> <p> Over $58m </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> Sapheon (Morrisville, NC, US and Galway, Ireland) </p> </td> <td> <p> Minimally invasive surgery </p> </td> <td> <p> Saphenous is running US FDA clinical trials of its VenaSeal sapheon closure system, a transcatheter technology that delivers medical adhesive to close the saphenous vein and treat venous reflux </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $19.8m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> Arsenal Medical (Watertown, MA, US) </p> </td> <td> <p> Biomaterials </p> </td> <td> <p> Arsenal is developing a therapeutic foam technology platform to control acute haemorrhage for military use, and also for clinical use </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> Advance Medical (Palo Alto, CA, US, Sao Paulo, Brazil) </p> </td> <td> <p> Medical device distribution </p> </td> <td> <p> Advance Medical specialises in medical device, equipment and diagnostics distribution </p> </td> <td> <p> Aberdare Ventures, Arboretum Ventures, Venrock and private investors </p> </td> <td> <p> $20m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> Intelomed (Pittsburgh, Pa, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Intelomed's CVInsight is a noninvaisve device for monitoring cardiovascular stability </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $4m </p> </td> <td> <p> Series A-1 </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> Bioconnect Systems (Ambler, PA, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> Bioconnect's Optiflow sutureless anastonotic connectors provide a fast repeatable method for connecting vessels. The firm is initially focused on devices that improve vascular access for end-stage renal disease patients undergoing haemodialysis. </p> </td> <td> <p> Ben Franklin Technology Partners and others </p> </td> <td> <p> $9.1m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Around $20.6m </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> OmniGuide Surgical (Cambridge, MA, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> OmniGuid is developing advanced energy surgical devices. It has launched the BeamPath Co2 laser System for minimally invasive surgery and used primarily in gynaecology and ENT procedures. </p> </td> <td> <p> Stata Venture Partners, Argonaut, Electro Scientific Industries </p> </td> <td> <p> $15m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> Neurotrack (Palo Alto, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Biomarkers to help with the diagnosis of Alzheimer's disease. </p> </td> <td> <p> Founders Fund, The Social+Capital Partnership and several angel investors </p> </td> <td> <p> $2m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> Practice Fusion (San Francisco, CA, US) </p> </td> <td> <p> Healthcare IT </p> </td> <td> <p> Practice Fusion has developed a free, web-based electronic record technology. </p> </td> <td> <p> Kleiner Perkins Caufield &amp; Byers, OrbiMed Advisors, Deerfield Management Company, Industry Ventures, Artis Ventures </p> </td> <td> <p> $70m </p> </td> <td> <p> Series D </p> </td> <td> <p> $134m </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> Apama Medical (Campbell, MA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Apama is developing an all-in-one, ablating, mapping and irrigation technology for treating atrial fibrillation. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $3.2m </p> </td> <td> <p> Series A-1 </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> OR Productivity (Guildford, UK) </p> </td> <td> <p> Surgery </p> </td> <td> <p> ORP's FreeHand surgeon-controlled camera holder allows surgeons to perform keyhole surgery more quickly </p> </td> <td> <p> Angel CoFund </p> </td> <td> <p> &pound;1m ($1.5m) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> SafeShot Technologies (Menlo Park, CA, US) </p> </td> <td> <p> Drug Delivery </p> </td> <td> <p> SafeShot supplies sterile, single-dose injectable medicaions in prefilled syringes. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> GenomeDx Biosciences (San Diego, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> The Decipher test is a molecular diagnostic that measures the aggressiveness of prostate cancer in patients who have had a prostatectomy and determines risk of disease progression, metastasis and prostate-related death </p> </td> <td> <p> Merck Global HEalth Innovation Fund, Baird Capital Partners, Aeris Capital, CD Ventures </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> September </p> </td> </tr> <tr> <td> <p> <b>October</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Verax Biomedical (Marlborough, MA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Verax Platelet PGD, based on Pan Genera Detection technology, is an FDA-cleared test to spot bacteria in donated blood platelets hours before transfusion. It works by detecting the number of shared antigents present in bacterial cell walls. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $12m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Amaranth Medical (Mountain View, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Amaranth is conducting CE mark clinical trials of its Fortitude bioresorbable coronary stent. </p> </td> <td> <p> DCP Management, Bio*Capital, Charter Life Sciences and Phillip Capital </p> </td> <td> <p> $20m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> iScreen Vision (Memphis, TN, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> iScreen Vision provides pediatric vision screening equipment and services. </p> </td> <td> <p> MB Venture Partners, Innova, and others </p> </td> <td> <p> $4m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> PixCell Medical Technologies (Yokneam, Israel) </p> </td> <td> <p> IVD </p> </td> <td> <p> PixCell specialises in cell-based diagnostics; it has a CE-marked HemoScreen complete blood count analyzer designed for point-of-care use. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> MedShape (Atlanta, GA, US) </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> MedShape develops soft-tissue repair devices based on its proprietary shape-memory foam. The latest product is the Eclipse anchor, a fixation device. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $11m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Personalis (Menlo Park, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Personalis has developed the ACE (Accuracy and Content Enhanced) technology used for advanced medical exome and genome sequencing and interpretation services. </p> </td> <td> <p> Lightspeed Venture Partners, Mohr Davidow Ventures, Wellington Shields and others </p> </td> <td> <p> $22m </p> </td> <td> <p> Series B </p> </td> <td> <p> over $42m </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Boreal Genomics (Los Altos, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Boreal's OnTarget platform performs genomic analysis of cell-free DAN in plasma to detect and quantify mutations in tumor-derived circulating nucleic acids. </p> </td> <td> <p> Arch Venture Partners, Kearny Venture Partners and others </p> </td> <td> <p> $18m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Protego Medical (Melbourne, Australia) </p> </td> <td> <p> Surgery </p> </td> <td> <p> Protego is developing a device for sternal protection during cardiac surgery. </p> </td> <td> <p> Medical Research Commercialisation Fund </p> </td> <td> <p> Aus$2m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Svelte Medical Systems (New Providence, NJ, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Svelte specialises in balloon expandable stents. </p> </td> <td> <p> CNF Investments, New Science Ventures, Apjohn Ventures Fund, Norwich Ventures and Svelte's founders </p> </td> <td> <p> $22m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $65m </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> PathoGenetix (Woburn, MA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> PathoGenetix has developed a next-generation sequencing, platform called Resolute. </p> </td> <td> <p> Ascension Health Ventures, Excel Venture Management, HEalthcare Ventures </p> </td> <td> <p> $10m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Securus Medical Group (Cleveland, OH, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> Securus is developing the Aurora thermographic mapping system, a thermal measurement device that can be used to monitor temperature during energy-based surgical procedures. </p> </td> <td> <p> 3x5 Special Opportunity, RiverVest Venture Partners, JumpStart, University of Michigan </p> </td> <td> <p> $6.5m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> CVrx (Minneapolis, MN, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> The Barostim neo is an implantable, carotid artery-stimulating system. It is CE marked for treating hypertension, but not approved yet in the US. It is also being trialled for treating heart failure. </p> <p></td> <td> <p> Ysios Capital, DaVita Healthcare Partners, New Enterprise Associates, J&amp;J Development, BBT Fund, SightLine Partners </p> <p></td> <td> <p> $12m </p> </td> <td> <p> Part of a $42m Series F </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Middle Peak Medical (Munich, Germany and Palo Alto, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Middle Peak is developing a technology for treating mitral valve disease. </p> </td> <td> <p> Edwards LifeSciences, BioMedInvest, Wellington Partners, Seventure Partners, High-Tech Gruenderfonds </p> </td> <td> <p> $3m </p> </td> <td> <p> Part of an $11m Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Trod Medical (Leuven, Belgium) </p> </td> <td> <p> Men's health </p> </td> <td> <p> The Encage is a percutaneous radiofrequency-based ablation device for treating prostate cancer </p> </td> <td> <p> Vesalius Biocapital, Capricorn Venture Partners, Gemma Frisius Fund, PMV </p> </td> <td> <p> Euros4.75m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Biodesix (Boulder, CO, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Biodesix develops molecular diagnostic tests for cancer based on its VeriStrate platform. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Monteris Medical (Plymouth, MN, US) </p> </td> <td> <p> Neurosurgery </p> </td> <td> <p> Monetris' NeuroBlate system delivers MRI-guided, laser-based therapy for brain lesions. </p> </td> <td> <p> BDC Venture Capital, SWMF Life Science Fund, and others </p> </td> <td> <p> $8.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> NextCODE Health (Cambridge, MA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> NextCODE, a spin-out of deCODE Genetics, uses gene sequence data to develop diagnotic tests </p> </td> <td> <p> Polaris Partners and Arch Venture Partners </p> </td> <td> <p> $15m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Kona Medical (Bellevue, WA and Menlo Park, CA, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> Kona's Surround Sound is an ultrasound-based noninvaisve system carrying out renal devervation to treat hypertension. </p> </td> <td> <p> Morningside Group, Domain Associates, Essex Woodlands, Morganthaler Ventures, Biostar Ventures </p> </td> <td> <p> $10m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Amaranth Medical (Singapore and Mountain View, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Amaranth's Fortitude is a fully bioresorbable heart stent. It is not yet CE marked nor US FDA-approved </p> </td> <td> <p> Bio*One Capital, Charter Life Sciences, Philip Ventures Enterprise Fund, </p> </td> <td> <p> $20m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> SpinalMotion (Mountain View, CA, US) </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> SpinalMotion has developed the Kineflex cervical disc implant for spinal surgery. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $10.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Lensar (Orlando, FL, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> The Lensar laser system is designed to perform refractive, laser-assisted cataract surgery. </p> </td> <td> <p> PDL BioPharma, Aisling Capital, Florida Growth, Florida Opportunity Funds, among others </p> </td> <td> <p> $27m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Kyma Medical Technologies (Israel) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Kyma is developing a miniature radar that uses microwaves to measure lung congestion in chronic heart failure patients. </p> </td> <td> <p> Ganot Capital, Elron Electronic Industries, Rafael Development Corporation </p> </td> <td> <p> $10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> CartiHeal (Tel Aviv, Israel) </p> </td> <td> <p> Regenerative medicine </p> </td> <td> <p> CartiHeal's Agili-C is a cell-free cartilage regeneration implant. </p> </td> <td> <p> Elron, Accelmed, Access Medical Ventures </p> </td> <td> <p> $5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> PulseOn (Finland) </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> PulseOn, a spinout of Nokia, is developing a heart rate monitoring device for the consumer market. </p> </td> <td> <p> Private investors </p> </td> <td> <p> Euro1m </p> </td> <td> <p> Seed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Sofie Biosciences (Culver City, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Sofie provides molecular imaging probe and devices for PET imaging. </p> </td> <td> <p> Tata industries, MRM Capital, the Cycad Group </p> </td> <td> <p> $5m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Genetic Analysis (Oslo, Norway) </p> </td> <td> <p> IVD </p> </td> <td> <p> The GA-map test is a DAN-based diagnostic for dysbiosis in patients with inflammatory bowel syndrome. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> JustRight Surgical (Boulder, CO, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> JustRight develops surgical instruments that allow access to confined and delicate structures. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $10.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Avenir Medical (Waterloo, Ontario, Canada) </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> Avenir is developing a suite of tools that can help surgeons more accurately perform joint replacements. </p> </td> <td> <p> MaRS Investment Accelerator Fund, angel investors </p> </td> <td> <p> $3.3m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Exagen Diagnostics (Albuquerque, NM,US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Exagen offers proprietary molecular diagnostic tests focused on rheumatology, such as tests for rheumatoid arthritis and lupus. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Swift Biosciences (Ann Arbor, MI, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Swift develops technologies for genomics and personalised medicine. It has a porfolio of Accel-NGS sample preparation products for next-generation sequencing. </p> </td> <td> <p> Renaissance Venture Capital Fund, Mercury Fund, Michigan Accelerator Fund and private investors </p> </td> <td> <p> $7m </p> </td> <td> <p> Series B </p> </td> <td> <p> $13m </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Precipio Diagnostics (New Haven, CN, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Precipio focuses on cancer diagnostics. </p> </td> <td> <p> Connecticut Innovations, Eli Whitney Fund, Ironwood Capital, Enhanced Capital, Kuzari Capital, and private investors </p> </td> <td> <p> $1.8m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> Insightra Medical (Irvine, CA, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> Insightra develops technologies used in hernia repair. </p> </td> <td> <p> Tekla Capital Management, Baird Capital, among others </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> October </p> </td> </tr> <tr> <td> <p> <b>NOVEMBER</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Solicore (Tampa, FL, US) </p> </td> <td> <p> Device components </p> </td> <td> <p> Solicore's Flexion ultra-thin flexible lithium polymer batteries can be used in micro medical devices. </p> </td> <td> <p> New Science Ventures </p> </td> <td> <p> $4m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> TriVascular (Santa Rosa, CA,US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> TriVascular sells its US FDA-approved and CE-marked Ovation and Ovation Prime abdominal stent grafts for aortic repair. </p> </td> <td> <p> New Enterprise Associates, Delphi Ventures, Kaiser Permanente Ventures, Kearny Venture Partners, Pinnacle Ventures, MPM Capital, Deerfield Management, Rock Springs Capiral, Permal Asset Management, Redmile Group </p> </td> <td> <p> $40m </p> </td> <td> <p> Series E </p> </td> <td> <p> Around $200m </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> Intact Medical (Framingham, MA, US) </p> </td> <td> <p> Oncology </p> </td> <td> <p> The Intact breast lesion excision system is designed to perform a biopsy for cancer diagnostics. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> LapSpace Medical (Misgav, Israel) </p> </td> <td> <p> Surgery </p> </td> <td> <p> LapSpace has developed an US FDA-cleared inflatable balloon retractor for use in laparoscopic procedures. </p> </td> <td> <p> Trendlines and private investors </p> </td> <td> <p> $1m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> GenapSys (Redwood City, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> GenapSys's next-generation sequencing platform is the GENIUS 110 (Gene Electronic Nano-Integrated Ultra-Sensitive). </p> </td> <td> <p> Yuri Milner, Stanford StartX Fund and other private and institutional investors </p> </td> <td> <p> $37m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> Scanadu (Mountain View, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Scanadu is using mobile and sensor technology to develop consumer-use diagnostic products, such as the Scanadu Scout vital sign monitor and ScanaFlo urine analysis test. </p> </td> <td> <p> Relay Ventures, VegasTechFund, Ame Cloud Ventures and other investors </p> </td> <td> <p> $10.5m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> Sensible Medical Innovations (Netanya, Israel) </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> Sensible has developed a home-based noninvasive thoracic fluid status monitor. </p> </td> <td> <p> Boston Scientific, Shanghai LongTec Medical Technology, SCP Vitalife Partners, Genesis Partners, TriVentures, BIRD-F and private investors </p> </td> <td> <p> $20m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> CardioInsight Technologies (Cleveland, OH, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> CardioInsight's ECVUE system is a heart monitoring technology that provides 3-D images to show the heart's electrical activity as it beats. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $15m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> Ablative Solutions (Menlo Park, CA, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> Ablative is developing a perivascular renal denervation technology for treating hypertension. The system delivers energy directly to the nerves, rather than through the artery walls like other renal denervation tehcnologies. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> Clear Catheter Systems (Bend, OR, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> Clear Catheter makes chest catheters that are used after heart surgery. The technology helps prevent problems from blood clots, a common complication after cardiac procedures. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $3.75m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> Surefire Medical (Westminster, CO, US) </p> </td> <td> <p> Oncology </p> </td> <td> <p> Surefire has developed and received global regulatory approval for its infusion systems that deliver embolic agents through a microcatheter to treat cancer site, while reducing damage to healthy tissue. </p> </td> <td> <p> MCG Partners, Partisan Management Group, High Country Ventures </p> </td> <td> <p> $18.2m </p> </td> <td> <p> Series B </p> </td> <td> <p> $24.3m </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> Biocartis (Lausanne, Switzerland) </p> </td> <td> <p> IVD </p> </td> <td> <p> Biocartis plans to launch its Idylla molecular diagnostics platform, designed to allow simple-to-use, rapid testing, in 2014. The first assay to run on the system is the BRAF cancer assay. </p> </td> <td> <p> RMM, Debiopharm Diagnostics, PMV Tina Fund, J&amp;J Development, Philips, the Wellcome Trust, Petercam, and other private investors </p> </td> <td> <p> &euro;30m </p> </td> <td> <p> Series E </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> Palmaz Scientific (Dallas, TX, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> The company specialises in applying nanotechnology to improve the performance of stents and implantable prostheses. The firm is founded by Dr Julio Palmaz who invented the balloon expandable stent </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $26.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> Pixium Vision (Paris, France) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Pixium is developing a intellient retinal implant system (IRIS) to restore vision in patients who suffer from degenerative retinal diseases. </p> </td> <td> <p> Sofinnova Partners, Omnes Capital, Abingworth, Bpifrance, Seventure, Global Life Science Ventures, Polytechnos </p> </td> <td> <p> $20m </p> </td> <td> <p> Series A-2 </p> </td> <td> <p> $33m </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> DxNA (St George, UT, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> DxNA's GeneSTAT molecular diagnostic platform offers portablem, simple, rapid and affordable PCR technology for detecting infectious diseases. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> iSTAR Medical (Isnes, Belgium) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> iSTAR has developed and CE marked the STARflo implant for managing intraocular pressure in glaucoma patients. </p> </td> <td> <p> Capricorn Health-Tech Fund, Societe Regionale d'Investissement de Walloni, Financiere Spin-off Luxembourgeoise, Namur Invest </p> </td> <td> <p> E4m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> Medina Medical (Menlo Park, CA, US) </p> </td> <td> <p> Neurology </p> </td> <td> <p> Medina is a stealth mode start-up developing minimally invasive devices for treating brain aneurysms and stroke. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $3.8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> Avalanche Biotechnologies (San Francisco, CA, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Avalanche is developing a biological drug delivery technology, BioFactory, for treating wet age-related macular degeneration </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5.7m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> Midatech (Abingdon, UK) </p> </td> <td> <p> Nanotechnology </p> </td> <td> <p> Midatech specializes in gold nanoparticle technology, which it is developing for insulin delivery (inside the patient's cheek) to treat diabetes, and for cancer treatment. Other applications of its technology include diagnostics, imaging, costmetics and electronics. </p> </td> <td> <p> Ippon Capital and others </p> </td> <td> <p> &pound;10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> November </p> </td> </tr> <tr> <td> <p> <b>DECEMBER</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Blaze Bioscience (Seattle, WA, US) </p> </td> <td> <p> Surgery </p> </td> <td> <p> Blaze's Tumor Paint is a proprietary agent that is desigend to help susrgeons in surgical excision of solid tumor by illuminating cancer cells intraoperatively in rela time and at high resolution. </p> </td> <td> <p> Individual investors </p> </td> <td> <p> $9m </p> </td> <td> <p> Series B </p> </td> <td> <p> $19m </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Biodesix (Boulder, CO, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Biodesix has developed the VeriStrat serum protein test to help guide personalized therapy for patients with non-small cell lung cancer. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $8.3m </p> </td> <td> <p> Series E </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Xlumena (Mountain View, CA, US) </p> </td> <td> <p> Interventional endoscopy </p> </td> <td> <p> Xlumena's CE-marked Axios stent and delivery system is a minimally invasive therapy for patients with gastrointestinal and biliary conditions. </p> </td> <td> <p> Prism VentureWork, Charter Life Sciences, Ascent Biomedical Ventures, Aperture Venture Partners </p> </td> <td> <p> $25m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Xagenic (Toronto, Ontario, Canada) </p> </td> <td> <p> IVD </p> </td> <td> <p> Xagenic is developing the first lab-free diagnostic platform, AuRA (Amplified Redox Assay) with a 20-minute time-to-result. </p> </td> <td> <p> Domain Associates, CRI Life Sciences Fund, Ontario Emerging Technologies Fund </p> </td> <td> <p> $20m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> DioGenix (Bethesda, MD, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> DioGenix is developing a next -generation sequencing assay that measures changes in human immunity. Its MSPrecise test evaluates if an individual is suffering from multiple sclerosis or another neurological disorder with similar symptoms. </p> </td> <td> <p> Nerveda </p> </td> <td> <p> $3.2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Cernostics (Pittsburgh, PA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Cernostics specializes in tissue-based diagnostics; its lead product is TissueCypher:Barrett's, which uses whole slide digital imaging technology to predict the risk of oesophageal cancer in patients with Barrett's Oesophagus. </p> </td> <td> <p> Novitas Capital, Geisinger Health System, Pittsburgh Life Sciences Greenhouse </p> </td> <td> <p> $1.4m </p> </td> <td> <p> Series B </p> </td> <td> <p> Over $6m </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Avinger (Redwood City, CA, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Avinger develops image-guided arthrectomy devices, based on its Lumivascular platform, for treating peripheral arterial disease </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Soft Tissue Regeneration (New Haven, CT, US) </p> </td> <td> <p> Regenerative medicine </p> </td> <td> <p> The company's US FDA-cleared Str graft is a biodegradable scafford to reduce patient's post-surgical pain following rotator cuff surgery. It is also developing products for knee ligaments. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $4.7m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Invitae (San Francisco, CA, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Invitae develops genetic diagnostics for hereditary disorders. </p> </td> <td> <p> Genomic Health, Randy Scott, Thomas McNerney &amp; Partners, Redmile Group, Genesys Capital, Casdin Capital, among others </p> </td> <td> <p> $40m </p> </td> <td> <p> Series E </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Gecko Biomedical (Paris, France) </p> </td> <td> <p> Surgery </p> </td> <td> <p> Gecko is developing novel biodegradable adhesives for surgical wound closure. </p> </td> <td> <p> Omnes Capital, CM-CIC Capital Finance, CapDecisif Management </p> </td> <td> <p> Euro8m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> AtheroMed (Menlo Park, CA, US) </p> </td> <td> <p> Peripheral vascular </p> </td> <td> <p> Atheromed is the developer of Phoenix, an athrectomy system for treating peripheral arterial disease below the knee. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $4.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Zyga Technology (Minnetonka, MN, US) </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> Zyga markets the US FDA-cleared SImmetry sacroiliac joint fusion syustem which treats sacroiliac joint dysfunction causing lower back and hip pain. </p> </td> <td> <p> Versant Ventures, Split Rock Partners, Domain Associates, MB Venture Partners, among others </p> </td> <td> <p> $10m </p> </td> <td> <p> Part of a $25m Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> SynCardia (Tucson, AZ, US) </p> </td> <td> <p> Cardiology </p> </td> <td> <p> SynCardia is the developer of the world's first and only US FDA-approved, CE-marked and Health Canada-approved temporary total artifical heart. </p> </td> <td> <p> SWK, Athyrium Capital Management, among others </p> </td> <td> <p> $14m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Metabolon (Durham, NC, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Metabolon specializes in discovering metabolomics biomarkers for diagnostic and therapeutic applications. It has deals to discover biomarkers related to cardiovascular diseases, multiple sclerosis, premenstrual dysphoric disorder (PMDD), amyotrophic lateral sclerosis (ALS), and type 1 diabetes and various cancers. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $15m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Mederi Therapeutics (Greenwich, CN, US) </p> </td> <td> <p> Gastroenterology </p> </td> <td> <p> Mederi has developed radiofrequency energy-based devices for treating diseases of the digestive system: Stretta for gastroesophageal reflux disorder (GERD) and Secca for bowel incontinence. </p> </td> <td> <p> Acadia Woods Partners, Respiratory Diagnostics (subsidiary of Bio-Rad), and private investors </p> </td> <td> <p> $18.5m (partly venture debt) </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Solx (Waltham, MA, US) </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Solx has developed the Gold Shunt, a 24-karat gold microimplant for reducing intraocular pressure caused by glaucoma. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2.1m (includes debt) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Intact Vascular (Wayne, PA, US) </p> </td> <td> <p> Peripheral vascular </p> </td> <td> <p> The Tack-It Endovascular System is a stapling device containing self-expanding tacks. It is designed to improve balloon angioplasty for treating peripheral artery disease by creating tissue apposition and smoothing the arterial lumen. </p> </td> <td> <p> Quaker Partners, HIG Bioventures, angel investors and others </p> </td> <td> <p> $4.7m (includes debt) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> CSA Medical (Baltimore, MD, US) </p> </td> <td> <p> Cryotherapy </p> </td> <td> <p> CSA has developed truFreeze, a catheter-based system that delivers spray cryogen inside the body to flash freeze and destroy unwanted tissue. </p> </td> <td> <p> Ascension Ventures, SV Life Sciences, Intersourth Partners, First Analysis, Blue Heron Capital, Rose Park and Guide Medical Ventures </p> </td> <td> <p> $16m </p> </td> <td> <p> Series C </p> </td> <td> <p> $48.6m </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Lineagen (Salt Lake City, UT, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Lineagen's FirstStepDx PLUS comprise a chromosomal microarray analysis, genetic counseling service and a detailed personalized report to help evaluate individuals with autism spectrum disorders. </p> </td> <td> <p> Signal Peak Ventures, Sanderling Ventures, PrairieGold Venture Partners, Mesa Verde Venture Partners, Archipel Capital, University Venture Fund, Hatteras Funds and Kickstart Seed Fund </p> </td> <td> <p> $3.5m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> ViewRay (Cleveland, OH, US) </p> </td> <td> <p> Oncology </p> </td> <td> <p> ViewRAy has developed a radiotherapy system comprising continuous soft-tissue imaging during treatment and MRI-guided radiotherapy. </p> </td> <td> <p> Aisling Capital, Fidelity Biosciences, Kearny Venture PArtners, OrbiMed Advisors, Cowealth Medical Holding </p> </td> <td> <p> $30m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> <tr> <td> <p> Rheonix (Ithaca, NY, US) </p> </td> <td> <p> IVD </p> </td> <td> <p> Rheonix's Encompass platform is designed to perform fully automated complex molecular assays in an easy-to-use and economical format. The first product from the platform is expected to launch in 2014. </p> </td> <td> <p> Cayuga Venture Fund,. Rand Capital SBIC </p> </td> <td> <p> $14m (includes debt) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> December </p> </td> </tr> </table> 
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 15

VC Funding 2013
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20160622T191408
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT061233
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 15

VC Funding 2013
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

339117
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T191616Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

cefba3aa-437f-4980-9ff4-bfbf5e1a9687
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T231408Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 14

sitecore\admin
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
